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"(...) Practicing transfusion is simply 
imitated Nature that, to nourish the fetus in 
the womb, make a continuous mother blood 
transfusion in the body of the baby through 
the umbilical vein" 
Jean-Baptiste Denis (1620-1704) 
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ABSTRACT OF PAPERS 
Produced during PhD and Post graduated course 
 
1. Rizzo C., Vetro R., Vetro A., Mantia R., Iovane A., Di Gesù M., Vasto 
S., Di Noto L.,Mazzola G., Caruso C. The role of platelet gel in osteoarticular 
injuries of young and old patients. Immunity and Aging 2014, 11:21. 
ABSTRACT 
Background: The use of autologous platelet gel in orthopedics is effective in 
accelerating the healing process of osteochondral, muscle, tendon and ligament 
lesions. The aim of our study was to verify whether the variability in response to 
infiltration with platelet gel was dependent on the underlying disease treated, sex 
and age of the patients. During four years, 140 patients have been treated for 
musculoskeletal injuries by infiltration of gel platelet and lysate platelet obtained 
from autologous thrombin, with echo-ultrasound guided. The response to 
treatment was assessed at different time points T0, T1, T2 with respect to pain 
estimation (VAS), joint mobility (ROM scale) and echo-ultrasound evaluation. 
This data collection has allowed classifying the response to treated lesions in 
three categories: NR (no response), PR (partial response), CR (complete 
response). Results: The data here reported showed that the ability to physical 
recovery response is evident in tendon injuries, while the large joints injuries 
gave a poor response. Almost all patients showed a significant pain relief after 
the first infiltration, but in terms of echo-ultrasound evaluation and tissue repair, 
only the muscle and tendon injuries showed hyper echoic areas, signs or 
evidences of repair. Concerning the correlation between response to infiltration 
with platelet gel and gender/age of the patients, the clinical results appear not 
influenced by the age and the gender of the patient. Discussion: Our data 
indicate that, pain relief and ability to physical recovery of muscles, tendons and 
ligaments depend on tissue repair clearly visible by echo ultrasound evaluation. 
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On the other hand tissue repair seems not occur in the large joints (hip and knee) 
where arthritis and /or corrosion of articular cartilage cannot be repaired and the 
only relief is exclusively linked to the reduction of periarticular inflammation 
(reduction of the inflammatory leakage and signs).  
2. Rizzo C., Caruso C, Vasto S. Possible role of ABO system in age-
related diseases and longevity: a narrative review. Immunity & Ageing 2014, 
11:16. 
ABSTRACT.  
ABO blood group antigens are expressed either on the surface of red blood 
cells either on a variety of other cells. Based on the available knowledge of the 
genes involved in their biosynthesis and their tissue distribution, their 
polymorphism has been suggested to provide intra species diversity allowing to 
cope with diverse and rapidly evolving pathogens. Accordingly, the different 
prevalence of ABO group genotypes among the populations has been 
demonstrated to be driven by malaria selection. In the similar manner, a 
particular ABO blood group may contribute to favor life-extension via biological 
mechanisms important for surviving or eluding serious disease. In this review, 
we will suggest the possible association of ABO group with age-related diseases 
and longevity taking into account the biological role of the ABO 
glycosyltransferases on some inflammatory mediators as adhesion molecules.  
3. Rizzo C., Accardi G., Caruso C. Genetic Variation in Human Leukocyte 
Antigen and Susceptibility to Acute Myeloid Leukemia. Acta Haematol. 2014 
Sep 27;133(2):162-163 
EXCERPTA 
In this issue of Acta Haematologica , the authors report the association 
between the human major histocompatibility complex (MHC) human leukocyte 
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antigen (HLA)-C3 and acute myeloid leukemia in the Korean population, 
confirming previous studies on the association between HLA-C and acute 
myeloid leukemia [1] . Following the demonstration by Lilly et al. [2] in 1964 of 
the increased risk of spontaneous or virus-induced leukemia in congenic mice 
with the H-2K (the MHC in mice), it is now over 40 years since the first 
associations between particular HLAs and leukemia and lymphoma diseases 
were described. These include a cross-reactive group of HLA-B and Hodgkin’s 
disease, HLA-A2 and acute lymphocytic leukemia (ALL) [3] . Over time, many 
studies on the association between HLA and the different kinds of leukemia 
have been performed showing contrasting results [3] . Following these 
pioneering studies, a broad spectrum of immune-mediated diseases, certain 
malignancies, longevity, infectious diseases, and adverse reactions to some 
drugs have been shown to be associated with allelic variants of HLA [4, 5] . So 
far, there appear to be no striking leukemia genetic susceptibility loci in HLA 
similar in nature and magnitude to those seen for autoimmune and infectious 
diseases. However, mounting evidence suggests that more modestly associated 
susceptibility loci showing population and type may exist [1, 3] . Nevertheless, 
the clear identification of a causative role for the HLA polymorphism in the 
pathogenesis of HLA-associated leukemia remains the exception rather than the 
rule. Advances in the understanding of MHC biological functions will enable 
comprehensive and definitive studies for evaluating the role of HLA in leukemia 
4. Rizzo C, Rizzo S, Scirè E, Di Bona D, Ingrassia C, Franco G, Bono R, 
Quintini G, Caruso C. Thrombotic thrombocytopenic purpura: a review of the 
literature in the light of our experience with plasma exchange. Blood 
Transfusion. 2012 Jun 27:1-12. 
EXCERPTA 
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Thrombotic thrombocytopenic purpura (TTP), a disease characterized by 
disseminated thrombotic microangiopathy associated with hemolytic 
microangiopathic anemia, was described for the first time by Eli Moscowitz in 
1925 as an "acute febrile pleiochromic anemia with hyaline thrombosis of the 
terminal arterioles and capillaries"
1
. The disease is now better understood from a 
pathophysiological point of view even though its rarity (annual incidence of 11.3 
cases per 1,000,000 population)
2
 and the lack of specificity of the signs, 
symptoms and laboratory findings make its management difficult. The 
symptoms, as stated, are non-specific: fever, renal dysfunction (to the point of 
acute renal failure in some cases), fluctuating neurological disorders (mild 
headache, onset of behavioral anomalies, transient sensory and motor deficits, 
coma), possible ischemic gastrointestinal complications (abdominal pain) and 
retinal detachment. More than 35% of patients do not have neurological 
symptoms at onset; fever and renal dysfunction are present in only a small 
minority of cases. The diagnosis can, therefore, be made in the presence of a 
microangiopathic hemolytic anemia (with schistocytes in a peripheral blood 
smear),thrombocytopenia (from platelet consumption) and increased levels of 
lactate dehydrogenase (LDH) not due to other identifiable causes 
3,4
. 
5. Vasto S, Scapagnini G, Rizzo C, Monastero R, Marchese A, Caruso C. 
Mediterranean diet and longevity in Sicily: survey in a Sicani Mountains 
population. Rejuvenation Res. 2012 Apr;15(2):184-8.  
ABSTRACT 
Over the past several years, increasing evidence suggests that the 
Mediterranean diet has a beneﬁcial inﬂuence on several age-related diseases, 
showing protective effect on health and longevity. Mediterranean diet refers to 
dietary patterns found in olive-growing regions of the Mediterranean countries. 
Previous data reported that in Sicily, Italy, the largest Mediterranean island, 
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there are some mountainous regions where there is a high frequency of male 
centenarians with respect to the Italian average. The aim of the present study was 
to characterize centenarians living in one of this region, the Sicani Mountains, 
located in western Sicily. Present data shows that in this zone there are more 
centenarians with respect to the Italian average. In fact, in the three villages of 
the Sicani Mountains, there were 15 people ranging from 100 to 107 years old, 
of the total population of about 10,000 inhabitants. This centenarian number was 
more than six-fold higher the national average (15.0 vs. 2.4/10,000); the 
female/male ratio was 1.5 in the study area, whereas the national ratio is 4.54. 
Centenarians living in these villages had anthropometric measurements within 
normal limits and moderate sensory disability without any sign of age-related 
diseases, including cognitive deterioration and dementia. In addition, their 
clinical chemistry proﬁle was similar to young controls and far better than that of 
old controls. Unequivocally, their nutritional assessment showed a high 
adherence to the Mediterranean nutritional proﬁle, with low glycemic index food 
consumed. Overall, close adherence to Mediterranean diet seems to play a key 
role in age-related disease prevention and in attaining longevity. 
6. Vasto S, Rizzo C, Caruso C. Centenarians and diet: what they eat in the 
Western part of Sicily. Immunity& Ageing. 2012 Apr 23;9(1):10. 
ABSTRACT.  
This paper pays attention to the modifiable lifestyle factors such as diet and 
nutrition that might influence life extension and successful ageing. Previous data 
reported that in Sicily, the biggest Mediterranean island, there are some places 
where there is a high frequency of male centenarians with respect to the Italian 
average. The present data show that in Sicani Mountain zone there are more 
centenarians with respect to the Italian average. In fact, in five villages of Sicani 
Mountains, there were 19 people with an age range of 100–107 years old from a 
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total population of 18,328 inhabitants. So, the centenarian number was 4.32-fold 
higher than the national average (10.37 vs. 2.4/10,000); the female/male ratio 
was 1.1:1 in the study area, while the national ratio is 4.54:1. Unequivocally, 
their nutritional assessment showed a high adherence to the Mediterranean 
nutritional profile with low glycemic index food consumed. To reach successful 
ageing it is advisable to follow a diet with low quantity o saturated fat and high 
amount of fruits and vegetables rich in phytochemicals. 
7. Di Bona D, Rizzo C, Bonaventura G, Candore G, Caruso C. 
Association Between Interleukin-10 Polymorphisms and Alzheimer's Disease: A 
Systematic Review and Meta-Analysis. J Alzheimers Dis. 2012 Feb 22.  
ABSTRACT. 
It has been hypothesized that polymorphisms of interleukin (IL)-10 genes 
affect the risk of developing late onset Alzheimer’s disease (AD). However, 
results of different studies are often inconsistent. Our aim was to investigate by 
meta-analysis the association of the common polymorphisms comprehensively 
deﬁning the genetic variability of the IL-10 gene with AD risk. Fifteen studies 
investigating the association between IL-10 polymorphisms (-1082, -819, -592) 
and AD were found and analyzed. The model-free approach was applied to 
meta-analyze these case-control genetic association studies. Available data 
suggested an association between -1082 polymorphism and AD risk with a 
marginal statistical signiﬁcance (GG versus AG/AA: pooled odds ratio [OR]: 
0.82, 95% conﬁdence interval CI: 0.65–1.02) and evidence of a moderate degree 
of between-study heterogeneity (χ2= 27.13, d.f. = 13, p = 0.01, I2= 52%). For 
the -819 and -592 polymorphisms, we did not ﬁnd an association with AD, but 
signiﬁcant between-study heterogeneity made genotype data pooling 
unacceptable. Analysis by IL-10 haplotype showed that the -1082G/-819C/-
592C haplotype is associated with a lower risk of AD, although with a marginal 
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statistical signiﬁcance, probably due to the low number of studies included 
(GCC versus other genotypes: OR: 0.61, 95% CI: 0.32–1.15; I2 : 85%). Current 
ﬁndings suggest a possible association between -1082 A>G polymorphism and 
the risk of developing AD; this effect is more evident in the oldest patients. The 
high degree of between-study heterogeneity, due to several underpowered 
studies and to other methodological problems of individual studies underlies the 
need for further methodologically adequate studies. 
8. Rizzo C, Castiglia L, Arena E, Gangi S, Mazzola G, Caruso C, Vasto S. 
Weak D and partial D: our experience in daily activity. Blood Transfus. 2012 
Feb 13:1-2 
EXCERPTA 
Dear Sir, 
The RH genes RHD and RHCE encode two proteins that represent the 
clinically most important blood group system defined by the sequences of red 
cell membrane proteins. RHD and RHCE, encoding the Rh proteins (D and 
Cc/Ee, respectively), are organised in tandem on chromosome 1p34-p36 and 
probably derived from duplication of a common ancestral gene. Many RH genes 
carry point mutations, or have rearrangements and exchanges between RHD and 
RHCE which result from gene conversion events. RHCE encode hybrid proteins 
that have RhCE-specific amino acids in RhD, or RhD-specific residues in RhCE. 
These might generate new antigens in the Rh blood group system, and alter or 
weaken expression of the conventional antigens
1,2
 
9. Vasto S, Caruso C, Castiglia L, Duro G, Monastero R, Rizzo C. Blood 
group does not appear to affect longevity a pilot study in centenarians from 
Western Sicily. Biogerontology. 2011 Jul 16.  
ABSTRACT  
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Centenarians are the best example of extreme human longevity, and they 
represent a selected population in which the appearance of major age-related 
diseases, such as cancer, and cardiovascular diseases among others, has been 
consistently delayed or escaped. The study of the long-lived individual genetic 
proﬁle has the purpose to possibly identify the genes and the allelic variations 
inﬂuencing extended life expectancy, hence considering them as biomarkers of 
age-related diseases onset and development. The present study shows no 
signiﬁcant differences between allelic variations of ABO blood groups among a 
group of centenarians from Western Sicily. 
10. Candore G, Bulati M, Caruso C, Castiglia L, Colonna-Romano G, Di 
Bona D, Duro G, Lio D, Matranga D, Pellicanò M, Rizzo C, Scapagnini G, 
Vasto S. Inflammation, cytokines, immune response, apolipoprotein E, 
cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. 
Rejuvenation Res. 2010 Apr-Jun;13(2-3):301-13  
ABSTRACT. 
Alzheimer disease (AD) is a heterogeneous and progressive 
neurodegenerative disease, which in Western society mainly accounts for senile 
dementia. Today many countries have rising aging populations and are facing an 
increased prevalence of age-related diseases, such as AD, with increasing health-
care costs. Understanding the pathophysiology process of AD plays a prominent 
role in new strategies for extending the health of the elderly population. 
Considering the future epidemic of AD, prevention and treatment are important 
goals of ongoing research. However, a better understanding of AD 
pathophysiology must be accomplished to make this objective feasible. In this 
paper, we review some hot topics concerning AD pathophysiology that have an 
important impact on therapeutic perspectives. Hence, we have focused our 
attention on inﬂammation, cytokines, immune response, apolipoprotein E 
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(APOE), cholesterol, oxidative stress, as well as exploring the related therapeutic 
possibilities, i.e., non steroidal anti inﬂammatory drugs, cytokine blocking 
antibodies, immunotherapy, diet, and curcumin. 
11. Cevenini E, Caruso C, Candore G, Capri M, Nuzzo D, Duro G, Rizzo 
C, Colonna-Romano G, Lio D, Di Carlo D, Palmas MG, Scurti M, Pini E, 
Franceschi C, Vasto S. Age-related inflammation: the contribution of different 
organs, tissues and systems. How to face it for therapeutic approaches. Curr 
Pharm Des. 2010;16(6):609-18.  
ABSTRACT.  
A typical feature of ageing is a chronic, low-grade inflammation 
characterized by a general increase in the production of pro-inflammatory 
cytokines and inflammatory markers (“inflamm-ageing”). This status may 
slowly damage one or several organs, especially when unfavorable genetic 
polymorphisms and epigenetic alterations are concomitant, leading to an 
increased risk of frailty together with the onset of age-related chronic diseases. 
The contribution of different tissues (adipose tissue, muscle), organs (brain, 
liver), immune system and ecosystems (gut microbiota) to age-related 
inflammation (“inflamm-ageing”) will be discussed in this review in the context 
of its onset/progression leading to site-restricted and systemic effects. Moreover, 
some of the possible strategies and therapies to counteract the different sources 
of molecular mediators which lead to the age-related inflammatory phenotype 
will be presented. 
12. Vasto S, Scapagnini G, Bulati M, Candore G, Castiglia L, Colonna-
Romano G, Lio D, Nuzzo D, Pellicanò M, Rizzo C, Ferrara N, Caruso C. 
Biomarkes of aging. Front Biosci (Schol Ed). 2010 Jan 1;2:392-402.  
ABSTRACT 
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Aging is a complex process that negatively impacts the development of the 
different systems and its ability to function.  Moreover, the Aging rate in humans 
is not the same, principally due to genetic heterogeneity and environmental 
factors. The aging rate is measured as the decline of functional capacity and 
stress resistance. Therefore, several attempts have been made to analyse the 
individual age, ( so-called biological age) compared to chronological age. The 
biomarkers of aging are age-related body function or composition, these markers 
aim to assess the biological age and predict the onset of age-related diseases 
and/or residual lifetime. Such biomarkers should help in one hand to 
characterize the biological age and on the other hand to identify individuals at 
high risk of developing age-associated diseases or disabilities. Unfortunately, 
most of the markers under discussion are related to age-related diseases rather 
than to age, so none of these markers discussed in literature is a true biomarker 
of aging. Hence, we discuss some disease-related biomarkers useful for a better 
understanding of aging and the development of new strategies to counteract it, 
essential for improving the quality of life of the elderly population.  
13. Iemolo F, Duro G, Rizzo C, Castiglia L, Hachinski V, Caruso C 
Pathophysiology of vascular dementia. Immun Ageing. 2009 Nov 6;6:13. 
ABSTRACT  
The concept of Vascular Dementia (VaD) has been recognized for over a 
century, but its definition and diagnostic criteria remain unclear. Conventional 
definitions identify the patients too late, miss subjects with cognitive impairment 
short of dementia, and emphasize consequences rather than causes, the true 
bases for treatment and prevention. We should throw out current diagnostic 
categories and describe cognitive impairment clinically and according to 
commonly agreed instruments that document the demographic data in a 
standardized manner and  undertake a systematic effort to identify the 
14 
 
underlying aetiology in each case. Increased effort should be targeted towards 
the  concept of and criteria for Vascular Cognitive Impairment and Post-Stroke 
Dementia as well as for genetic factors involved, especially as these categories 
hold promise for early prevention and treatment. 
14. De Luca G, Santagostino M, Secco GG, Cassetti E, Giuliani L, Franchi 
E, Coppo L, Iorio S, Venegoni L, Rondano E, Dell'Era G, Rizzo C, Pergolini P, 
Monaco F, Bellomo G, Marino P Mean platelet volume and the extent of 
coronary artery disease: results from a large prospective study. Atherosclerosis. 
2009 Sep;206(1):292-7.  
ABSTRACT.  
Background: Platelets play a central role in the pathogenesis of coronary 
artery disease. Mean platelet volume (MPV) is an indicator of platelet activation, 
and has been demonstrated to be correlated with platelet reactivity. The aim of 
the current study was to investigate whether mean platelet volume is associated 
with the extent of coronary artery disease. Methods: We measured MPV in 1411 
consecutive patients undergoing coronary angiography. All angiograms were 
analyzed by two investigators blinded of clinical data. Signiﬁcant coronary 
artery disease was deﬁned as stenosis >50% in at least 1 coronary vessel. We 
additionally measured Carotid Intima-Media Thickness (IMT) in 359 patients. 
The relationship between MPV and platelet aggregation was evaluated by PFA-
100 in 50 consecutive patients who were not taken any antiplatelet therapy, and 
in a cohort of patients who were on aspirin by PFA-100 (n = 161) and Multiplate 
(n = 94). Results: Patients were divided into three groups according to tertiles of 
MPV. Patients with higher MPV were slightly older (p = 0.038), with larger 
prevalence of diabetes (p < 0.0001), hypertension (p = 0.008), previous CVA (p 
= 0.041), less often with stable angina (p = 0.043) and family history of CAD (p 
= 0.011), more often on statins (p = 0.012), and diuretics (p = 0.007). MPV was 
15 
 
associated with baseline glycaemia (p < 0.0001) and red blood cell count (p = 
0.056), but inversely related to platelet count (p < 0.0001). MPV was not 
associated with the extent coronary artery disease (p = 0.71) and carotid IMT (p 
= 0.9). No relationship was found between MPV and platelet aggregation. 
Conclusion: This study showed that MPV is not related to platelet aggregation, 
the extent of coronary artery disease and carotid IMT. Thus, this parameter 
cannot be considered as a marker of platelet reactivity or a risk factor for 
coronary artery disease. 
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PEX Plasma Exchange 
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1. INTRODUCTION 
 
1.1 HISTORY OF TRANSFUSION MEDICINE  
 
It is very difficult to date the beginning of transfusion medicine, since the blood 
has always been considered a key element in  healing of many diseases. 
The transfusion medicine history, in fact, begins with the transfusion and was 
marked by scientific knowledge of the last decades around the turn of the 19th into 
the 20th centuries: an increasing appreciation of a potential role in the management 
of surgical and obstetric bleeding, in severe non-surgical anemia, has transformed 
completely the history of transfusion medicine.  
The blood transfusion has legendary and controversial origins.  
One of the earliest manuscripts on the history of transfusion is dated 1875
1
 (Frati 
et al 2005). The author distinguishes three periods: a period "mythological", 
empirical and legendary that ends with the discovery of the blood circulation (1628). 
An "experimental" period begins with1628 to the end of the seventeenth century. A 
"therapeutic" period from the first 800 to the present day (table 1) 
The mythological period has scarce and nuanced sources and is linked to the 
classical tradition. 
In the classical tradition, in fact, blood was considered "lifeblood", seat of the 
soul and magical power. During the rites, the blood of the sacrificed victims was 
offered to gods as a gift. The warriors' tribes drank the enemies' blood to draw 
strength.  
The first blood transfusions may already have been practiced by Egyptians, 
Greeks and Romans. 
                                                          
1 DE CRISTOFORIS M., La trasfusione del sangue. Milano, Rechiedei, 1875. 
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As known, Egyptian physicians successfully performed brain surgery, so it is 
possible that the transfusion could be known and practiced. Also in ancient Egypt 
transfusion could be practiced as a geriatric care to prevent pharaoh’s aging. The 
Egyptian papyri and the ancient temples inscriptions, in fact, handed down that 
Egyptian priests used the blood to cure the princes "oppressed by diseases of 
languor." For nearly 2,000 years, in Egypt the blood was regarded as the sovereign 
remedy for leprosy. The two greatest exponents of the School of Alexandria, 
Herophilus of Chalcedon (III aC). and Erdasistrato of Giulide, use the verb "to 
transfuse" although it is doubtful that this refers to the practice exactly as we know it. 
(Frati et al 2005). 
Some Jewish writings tell the story of a Syrian prince cured of leprosy with oral 
fresh blood administration. This suggests that the ancients would used the blood for 
the diseases treatment or for the rejuvenation. 
Hippocrates (460-355 aC), the Greek physician and modern medicine pioneer, 
prescribed blood administration in the treatment of the "falling sickness" although 
the mode of administration is not specified  
In Roman times, the blood administration was oral exclusively. Empirical 
evidences showed that patients drinking blood were healed easily. So, the blood had 
healing power.  
The ancient Rome’s history haven’t got transfusion’s news. In a legend 
Tanaquilla, Tarquinius Priscus's wife, (577 aC), gave her blood to husband stabbed. 
The  oral blood administration efficacy , was known to Celsus (60 aC: De Medicina 
VIII) and Pliny the Elder (23 d.C: Naturalis histories). They say that epileptics drank 
the warm blood of just killed gladiator. Tertullian (150 d.C) recommended the blood 
use in the treatment of debilitating conditions.  
The first mentioned transfusion, regards Ovid's Metamorphoses (43 aC - 17 dC): 
Medea, learned the Egyptian priests' art used blood to rejuvenate old Exon. She took 
his blood by phlebotomy and led into his veins a "mood secret" able to rejuvenate. 
20 
 
This technique, used by the Romans to rejuvenate, was called "medeana care". For a 
long time remained the idea that the blood transfusion could rejuvenate. In fact, in 
the Renaissance Marsilio Ficino (1433-1499) recommended to drink the blood of 
young people to rejuvenate. There are a lot of information about the use of 
transfusion therapy in the Middle Ages. It is known that bloodletting therapy was 
frequent for release negative moods responsible of disease. Alternating purges, 
bloodletting was performed without any criteria and without any hygiene. The 
physician did a simple incision into a vein and let out half liter or liter of blood in the 
hope of freeing the patient from the disease. This practice was often repeated many 
times until then cause severe anemia and the sick was weak and vulnerable to other 
diseases. The practice of bloodletting became very popular so that the bloodletting 
practice was given to the barbers who hung out the door the wet blood bandages. 
From here the signs in red and white stripes of the barbers. The wide spread of 
bloodletting increased the number of deaths. Soon everyone realized that removing 
the blood did not help to heal any sick and that could be useful to give more blood to 
the sick (Frati et al 2005).  
Thus was born the theory of transfusion.  
The first documented blood transfusion seems to have been practiced to Pope 
Innocent VIII in 1492: a Jew physician used the blood of three children under 10 
years to cure the pope. The children died and the pope didn't heal. 
However, in this time, the transfusion history is between myth and reality and the 
cited sources narrate popular beliefs without scientific support. The mythological 
period, in fact, was concluded with first scientific studies of Realdo Colombo (1558). 
He studied the blood’s path in the arteries and pulmonary veins and led to description 
of cardiovascular circuit by William Harvey in 1628. (fig. 1) 
This finding suggested to transfuse blood directly into veins with rudimentary 
methods (urinary animals bladders, porcupine quills, heavy silver tubes). With these 
discoveries begins the experimental period and the first description of blood 
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transfusion process. With regard to techniques used for transfusion, in 1660 
Francesco Folli (1624-1685) explained that was necessary to insert a silver cannula 
in a donor artery and an ivory cannula in a recipient vein. The two cannulas had to be 
connected by an elastic tube (Frati et al 2005).  
These experiments spread rapidly in England, France, Germany and Italy, until in 
1663 the Philosophical Society of London commissioned to physicians Daniel and 
Thomas Coxe to investigate about blood infusion and transfusion. They studied the 
effects of blood infusion in same and in different species animals. Also, they 
observed the effects from artery to vein and from vein to vein transfusion. 
The observation that from these experiments weren't derived harmful 
consequences for  animals, led to the first attempt to heterologous transfusion in 
humans. Jean-Baptiste Denis (1620-1704), physician of the court of Louis XIV, on 
March 3, 1667 transfused 16 years old young affect by unknown fever with lamb's 
blood (after twenty bloodletting in two months without success). The amount of 
blood transfused was nine ounces (270 gr.) (fig.2) 
The patient's recovery and the experiment success was huge and spread in the Old 
Continent quickly. A large number of heterologous human transfusion was 
implemented to treat human diseases. 
In London, Lower and King, using heterologous transfusion to treat mental 
illness, described methods for artery to vein transfusion and problems related to 
blood clots formation in the "Tractatus de Corde idem et de motu et colore 
sanguinis" (1669). In fact, the formation of blood clots in transfusion devices, was a 
real problem and begin the first rudimentary anticoagulants methods. At the time, in 
Germany, Mayor Jean Daniel (1667), describes "semi direct" transfusion and 
proposes a few grains of salt or deer horn or flower salt ammoniac to prevent blood 
clotting in pipes' silver. 
In subsequent years, the blood heterologous transfusion spread quickly to cure 
very different diseases: insanity, chronic anemia, tuberculosis, stubborn fevers, 
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stomach cancer, typhoid without special precautions to prevent adverse reactions . 
The history don't report transfusion cases to treat acute hemorrhage anemia in this 
time. 
The number of heterologous transfusions increased together with number of very 
dramatic failures. This procured many disappointments and the initial supporters 
enthusiasm was opposed to hostility of the most respected scientists.  
In a hot climate, when the patient treated by Jean-Baptiste Denis died, the 
patient's family sued the physician at the Assize Court of the Chatelet. The death had 
occurred from arsenic poisoning, but the court of Paris (with a decree became law 
January 10, 1670) forbad in France the human blood transfusion. At that time, 
French culture ruled the roost in the scientific community: the English Parliament 
and the Pope adopted the same measure. Bartolomeo Santinello, Italian physician of 
the XVIII century, declared necessary to ban this operation for the "good of 
humanity"(Frati et al 2005).  
The transfusion history and disputes between supporters and opponents came to 
the end and transfusions were not practiced throughout the XVIII century. 
In the early XIX century occurred revival interest for transfusion medicine. At 
that time there was a general climate of interest in new medicine discoveries. An 
Italian physician, Michele Rosa (1731-1812), started interesting experiments on 
blood animals. He revived the correct setting of the animals experimental blood 
transfusion and studied psychomotor manifestations on animals brought to the death 
by total bloodletting. 
So scientists studied causes and pathophysiology of blood transfusion 
consequences and thus began the therapeutic period (evolving today). 
In 1818, the British obstetrician James Blundell (1790-1878), demonstrated the 
incompatibility of heterologous transfusions and the need to use human blood for 
humans. For the first time, he performed a successful transfusion of human blood to 
a patient with postpartum hemorrhage. He used husband’ blood (as a donor) to 
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perform arm to arm transfusion. He also devised the use of autologous blood for 
transfusions, recovering that lost in women with postpartum hemorrhage. Blundell 
introduced two instruments for the purpose of transfusion: the impellor and the 
gravitator. The impellor was a complex invention consisting of a cup, tube and 
syringe. When using the gravitator, blood was injected into the patient via a tube 
suspended from a vessel held high above the patient. Information on both 
apparatuses was published in The Lancet in 1829. (Fig 3) 
The patients’ observation after transfusion has allowed to describe post 
transfusion clinical features: shivering with fever, anxiety, thirsty air, tachycardia, 
hematuria, cyanosis, dyspnea, cough with frothy bleeding sputum, distended jugular 
veins. These complications were due to incomprehensible phenomena in those days: 
incompatibility, overload, contamination for lack sterility, imperfect knowledge of 
bood composition. The scientists understood that these effects were due to the 
different species of blood, therefore was prohibited heterologous transfusion.  
In 1882, Julius Friedrich Cohnheim (1839-1884) introduced the "blood 
compatibility" that led to practice exclusively inter-human transfusions: post-
transfusion accidents were reduced greatly, but the failures were not entirely 
disappeared. So, the research had found a new area of interest: to know and 
characterize the blood to understand the differences between individuals of the same 
species (Boulton 2013. Part 1). 
Among all the researchers, the most famous name is Karl Landsteiner (1868-
1943), considered the father of immunogenetics and the initiator of the transfusion 
science. He discovered that red blood cells of individuals can differ antigenically and 
found the properties of red blood cells agglutination. Using serological methods, he 
had been impressed that “the proteins in various animals and plants are different and 
are specific for each species.” He wondered “whether … individuals within a species 
show similar … differences. As no observations whatever were available pointing to 
such behavior, I chose the simplest among the possible plans of investigation … 
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allowing blood serum and red blood corpuscles of different human individuals to 
interact” (Lansdteiner 1931). In fact, by simply mixing serum and erythrocytes from 
different person and comparing their pattern of reactions, he could classify blood into 
three groups. The occurrence of agglutination indicated the existence of natural or 
preexisting antibodies against foreign blood groups. In the 1901 paper he tabulated 
the results of complete cross-testing of the sera and cells of six people working in his 
lab, including himself (fig 4). He noted first that the serum of none of the six 
individuals reacted with the person's own cells—a clear observation of self-tolerance 
(Owen 2000) 
Those with group A blood cells had antibodies to group B cells; those with group 
B blood cells reacted with group A cells; and the serum of group C people 
agglutinated erythrocytes of both group A an B people. Today group C in known as 
group O. The fourth group, AB, was discovered a year later, and these rare 
individuals lack both isotypic agglutinating antibodies. Landsteiner' s work led to a 
reduction in the risk of blood transfusions, which had previously and unpredictably 
resulted in toxic shock: it provided a scientific explanation and a method for 
determining transfusion compatibility. In 1901, Landsteiner classified blood groups 
(ABO) and found that their determination depended on hereditary factors, 
transmitted from generation according to Mendel's laws. He received the Nobel Prize 
for Medicine in 1930 for this discovery (Boulton 2013. Part 1).  
The diversity of blood groups among individuals, gave a new understanding of 
transfusion: it’s necessary to seek donor and recipient RBC characteristics and to 
respect the patterns of compatibility. This has increased the safety of blood 
transfusions and reduced postoperative deaths. The concept of donor and recipient 
compatibility was enhanced in 1907 when Hektoen introduced compatibility testing 
combining in vitro blood donor and blood recipient to exclude incompatibility (cross 
match).  
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The first four blood groups to be discovered not distinguish individuals, but with 
the addition of the minor erythrocyte antigens, individualistic sets emerged. In the 
1908, Ehrlich and Morgenroth (Kaufmann S 2008), the fathers of immunology, had 
early shown that when blood of one goat was injected into another goat immune 
antibodies that reacted with the donor’, not the recipient’s cells appeared and that 
these antisera recognized a complexity of individual differences among goats. By 
1910, Todd and White had published similar studies of cattle and chickens, work 
indicating that any individual within a species had an almost unique individuality. 
Landsteiner wondered why, given a match for ABO, human transfusions did not 
readily reveal such individuality with Levine (1927); tried injecting rabbits with 
human blood and using the immune sera to detect differences among people. This led 
to the next marker for human genetics, the M-N alternative, later to prove so 
complicated. The same experiments revealed the P groups.  
The immuno-haematological knowledge were complied in 1940 when Landsteiner 
and Wiener discovered "Rh" factor (or Rhesus factor), an blood cells antigen involved 
to pre transfusion compatibility. They inject cells from Rhesus monkeys into guinea 
pigs and rabbits and see if the resulting antisera distinguished human characteristics 
(Owen 2000). This led to the recognition of the Rh system, named for the Rhesus 
donors; they discovery Rh factor in human blood and classified human population in 
Rh positive and Rh negative depending on red blood cells agglutination with anti-
Rhesus serum.  
Blood incompatibility in the special jet common circumstance of the Rh antigen 
can be fatal and id the theme of a report by Philip Levine (1941) and his colleagues. It 
concerns how one self accepts or rejects another self within its territory, specifically 
how an Rh negative mother becomes sensitized to and subsequently kills an Rh 
positive fetus developing within her. The disease is erythroblastosis fetalis and the 
milestone established its immunological origin. Levine’s team knew that, like ABO 
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blood groups, the Rh antigen was inherited by Mendelian process, but the underlying 
genetics mechanisms were unknown.  
However the main hazard, perceived from early attempts, was ordinary blood 
clotting, not blood group incompatibility. After the anatomical demonstration of the 
blood circulation and the blood groups identification, it was necessary to have not 
coagulated blood for transfusions.  
When blood was taken from a prospective donor, it clotted during the transfusion 
process, to conspicuously ill effect on the recipient. Shortly after 1900 surgeons 
developed extraordinary methods of joining an artery of the donor with a vein of the 
recipient so that the blood was not exposed to clotting during transfer (direct 
transfusion).  
At the beginning of the last century (1902), the pharmacologist Luigi Sabbatini 
(1863-1928) discovered anticoagulant properties of sodium citrate (Mann 2007). It has 
revolutionized the transfusion technique because transforming direct in indirect 
transfusion. Also, he found that citrate preserve long and unaltered blood characteristic 
allowing blood storage at 4-6° C in containers for a few days after collection.  
This discovered was very important because the use of an anticoagulant (citrate) 
solved the clotting problems and allowed the extensive use of transfusions in the First 
World War. The first transfusion of citrated blood given to a human seems to have 
been performed by Hustin (1914) (Mollison 2000).  
In 1918, Oswald Robertson added dextrose to sodium citrate obtaining the 
anticoagulant solution ACD (citric acid-citrate-dextrose) that allowed blood storing up 
to 21 days and published a remarkable paper, describing transfusions of stored red 
cells given near the front line in France in the First World War (Robertson 1918). Only 
4 years had elapsed since the first few transfusions of citrated blood had been given to 
human subjects; the method of storage which was used had not previously been 
applied to transfusion in humans. Robertson used a bottle with a capacity of 900±1000 
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cc; 160 cc of 3,8% citrate was used and marks made on the bottle at 660 
corresponding to 500 cc blood, etc. (Fig 5).  
For the first time, a bank of units of stored blood was created and shown to be of 
great practical value. The first Transfusion Centre was organized in Paris at the 
Hospital Saint Antoine in 1923; later many other centers sprang up across Europe and 
America. In 1930 was formed the first "Blood Bank" at the London Hospital. 
The transfusion improvements and increased transfusion requirements during the 
Second World War, gave a strong boost to transfusion research. 
In 1947 was formed the American Association of Blood Banks (AABB) to 
promote common results between the transfusion centers. The US government, to 
ensure improving assistance to military troops, financed many research projects. Thus 
began a spontaneous donation publicity based on solidarity: in the cities war involved 
were hung posters that reminded: "Donate blood, now!", "Your blood can save him" 
and "He gave his blood. How about you? ". Thus were born the association aimed at 
blood donation. In the United States, during the Second World War, were given 
about 13 million units of blood. It is estimated that in London they have been 
collected and distributed more than 260,000 liters. After Second World War, 
important medicine improvements made possible surgeries unimaginable once. 
In 1952, Carl Walter introduced the plastic blood bags for the blood collection, 
indispensable for simple and safe collection system. 
Furthermore it was introduced the refrigerated centrifuge which allowed to 
separate multiple blood components from a single blood unit: in this way it is 
possible to separate red blood cells, plasma and platelets from whole blood. This 
represented a real revolution for transfusion medicine because with the blood  
components it's possible to transfuse the patient only what is needed to cure. In fact, 
according to clinical indications, it is possible to administer individual blood 
fractions, plasma and blood components (red blood cell, white cell, platelet, human 
plasma and its fractions).  
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This opens the era of actually transfusion medicine, in which the transfusion 
physician, specifically trained, participates in the sick care actively. 
29 
 
 
HISTORY OF TRANSFUSION MEDICINE: HISTORICAL PERIODS 
MYTHOLOGICAL 
PERIOD 
 Blood is considered "lifeblood", seat of the soul and magical power 
in the Egyptian papyri and Jewish writings 
 The first blood transfusions may already have been practiced by 
Egyptians, Greeks and Romans.  
 Hippocrates (460-355 aC), prescribed blood administration in the 
treatment of the "falling sickness" 
 In roman times exclusively blood oral administration  
 Ovid's Metamorphoses (43 aC - 17 dC): first mentioned transfusion 
for disease’s treatment or for the rejuvenation (“medeana care”)  
 In the Middle Ages was frequent bloodletting therapy for  release 
negative moods responsible of disease. 
 The first documented blood transfusion has been practiced to Pope 
Innocent VIII (1492) 
 The transfusion history is between myth and reality 
EXPERIMENTAL 
PERIOD 
 1558: Realdo Colombo described the blood’s path in the arteries and 
pulmonary veins 
 1628: William Harvey  described cardiovascular circuit  
 1660: Francesco Folli inserted a silver cannula in a donor artery  
and a ivory cannula in a recipient vein and connected with an elastic 
tube. 
 1667: Jean-Baptiste Denis performed first direct heterologous 
human transfusion  
 1670 the Assize Court of the Chatelet  (Paris) forbad in France the 
human blood transfusion . 
 In Europe transfusions were not practiced throughout the XVIII 
century 
THERAPEUTIC PERIOD 
 1818: James Blundell demonstrated the incompatibility of 
heterologous transfusions and the need to use human blood for 
humans  
 1882, Julius Friedrich Cohnheim introduced the "blood 
compatibility" 
 1901: Landsteiner classified blood groups (ABO) 
 1902: Sabbatini discovered blood anticoagulant (citrate) 
 1907: Hektoen introduced compatibility testing 
 1914:First transfusion of citrated blood given to a human performed 
by Hustin  
 1918: Oswald Robertson added dextrose to sodium citrate obtaining 
the anticoagulant solution (ACD). Begin the blood banking 
 1923:First Transfusion Centre in Paris at the Hospital Saint Antoine  
 1927: Landsteiner and Levine discovered erythrocyte's minor 
antigens (MN and P)  
 1930: First "Blood Bank" at the London Hospital. 
 1940: Landsteiner and Wiener discovered "Rh" factor 
 1941: Philip Levine discovered erythroblastosis fetalis and 
established its immunological origin 
 1947: Beginning of American Association of Blood Banks (AABB) 
 1952: Carl Walter introduced plastic blood bag 
Table 1: M. De Cristofori (La trasfusione del sangue, 1875) distinguishes three periods:  
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a period "mythological", empirical and legendary that ends with the discovery of the blood 
circulation (1628). An "experimental" period begins with 1628 to the end of the seventeenth 
century. A "therapeutic" period from the first 800 to the present day 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. William Harvey (1578-1657) Image of veins from Harvey's exercitatio 
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Fig 2. Jean-Baptiste Denis (1620-1704): First direct transfusion between human and animals 
and used instruments 
32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3 .Perpendicular section of the Impellor, a complex invention consisting of a cup, tube and 
syringe published in The Lancet in 1829 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 4. Karl Landsteiner, 1931. Photo  of the National Academy of Sciences. Table: the results of 
complete cross-testing of the sera and cells of six people working in his lab including himself 
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Fig 5. Robertson's bottle for citrate transfusion. (A) Line from donor. (B) Line to recipient (C) 
Rubber bulb with valve (Higginson's syringe), supplying either negative or positive pressure. (D) Marks 
are made on the bottle (which has a capacity of 900±1000 cc) at 160, 660, 760 and 860 cc; citrate is 
added to the 160 mark and the donor is bled to one of the upper marks, corresponding to 500±700 cc 
blood (Mollison P.L. British Journal of Haematology, 2000; 108: 15) 
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1.2 CONTEMPORARY TRANSFUSION MEDICINE: the last 20 years of 
discovery 
The last few decades have been very important for transfusion medicine history. In 
particular, some innovative therapy techniques and cellular manipulation, have 
radically changed the transfusion medicine services identity and have had a huge 
impact on patient care. 
In fact, the main scientific findings include: apheresis technology, marrow and 
hematopoietic stem cells, RBC antigens and antibodies, the role of the WBC, PLT and 
neutrophil antigens and antibodies, volunteer blood donors, blood safety, 
hematopoietic growth factors, plasma derivatives, blood utilization and management. 
Our attention will be focused in particular on four key aspects of modern 
transfusion medicine: therapeutic apheresis, regenerative medicine, stem cells and 
molecular biology. 
The aphaeresis is based on the principle of the whole blood separation by 
extracorporeal circuits. It 'a very sophisticated technique that allows to isolate the 
blood elements (liquid or corpuscular) and to manage them independently. The donor 
of multicomponent and the blood recipient are not exposed to significant risks. The 
physician responsible (before the procedure) explains possible risks and the patient or 
donor accepted and expressing their informed consent. 
The therapeutic application of these techniques, has radically changed the natural 
history of many diseases.  
The ability to use non transfusion blood components , has opened new frontiers in 
transfusion medicine. Using bioregenerative capacity of platelets growth factors, it's 
possible to intervene in many clinical areas (surgical and aesthetic) to promote the 
regeneration of damaged tissues or to tissue repair. 
In relation to these arguments, there is a growing scientific interest. A very strong 
push was given by the integration of apheresis and tissue regeneration. This has led 
over the past 20 years using aphaeresis to produce stem cells using peripheral blood. 
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The bone marrow is rich in stem cells. The recruitment of bone marrow donors 
community volunteers represented the beginning of clinical use of stem cells. In recent 
years, was possible to increase the number of peripheral blood stem cells and allow the 
removal of the stem cells by aphaeresis. This improvements opened the way to many 
novel cellular therapy. Blood banks took the lead in marrow donor recruitment. 
Last important aspect of contemporary transfusion medicine is the use of molecular 
biology. The application of molecular techniques for the genetic study of erythrocyte 
antigens, for example, has strong implemented immunohaematological knowledge and 
has solved many transfusion problems. In particular, today, they are widely used for 
extended red cell antigens typing (minor red cell antigens and allelic Rh variants) for 
the banking of rare red blood cells. Obviously in the transfusion field the technique is 
applied to the stem cells molecular HLA typing and is used as improvement for the 
diagnosis of many diseases treated by transfusion medicine (genetic study of 
hemoglobinopathy or PPT). 
 
1.2.1. Therapeutic Apheresis 
The first episode of use of aphaeresis in humans, dating back to 1930, when 
Soloman and Fahey used plasmapheresis in treatment of macroglobulinemia of 
Waldestrom, an hyperviscosity syndrome. (Salomon 1962) The therapy consisted of 
removal patient's plasma and reinfusion of isotonic saline. In this way hyperviscosity 
due to immunoglobulin excess had correct and had improved the clinical symptoms 
(Raynolds 1981). The plasma exchange, was symptomatic therapy because corrected 
the symptom (hyperviscosity) and didn’t act on the causes (excess immunoglobulins 
production).  
The first device for therapeutic aphaeresis dates 1962, when IBM and the National 
Cancer Institute in Bethesda (USA) designed a prototype centrifuge to remove the 
white blood cells. Since then, the therapeutic removal of cells or pathological 
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molecules was carried out by different methods, developed according to different 
pathophysiological mechanism’s disease. The knowledge of the pathophysiological’s 
diseases, has encouraged the development of different apheretic techniques with 
appropriateness prescriptive. 
The principle of therapeutic aphaeresis, is the selective removal of pathogens or 
excessive blood components (cells or molecules). This removal is performed using 
extracorporeal circulation technique and anticoagulants (citrate or heparin) to prevent 
blood clotting. In the last decade, technological change and computerization improved 
the existing techniques and promoted more selective removal of pathological particles 
in the plasma (LDL cholesterol, fibrinogen, immunoglobulin, circulating immune 
complexes, toxins) and collection of cellular elements (platelets, leukocyte, 
lymphocyte stem cells). 
The therapeutic aphaeresis techniques can be grouped into three major groups: 
exchange cell therapy (plasma exchange/ erytroexchange), plasma treatment and 
therapeutic erythrocytaphaeresis. 
 
a. Plasma exchange (PEX): PEX consists in removing the plasma patient and 
the replacement with substituent solution (fresh frozen plasma, electrolytic solutions, 
albumin). The pathogenic molecules are removed with the plasma, changing the 
natural history of the disease. According to international guidelines ASFA (American 
Society for Apheresis), PEX can be considerate the I or II line treatment (category I 
and II) and usually is compensated with drug therapy to act on the causes of disease. 
The PEX treatment consist in multiple cycles that includes daily treatments on 
consecutive days. In each daily treatment are defined exchanged volume, treatment 
frequency and type of substituent solution according to ASFA guidelines. Each PEX 
procedure comprises several cycles consisting of two step: a step for blood collection 
and a step for reinfusion. After collection, the blood is centrifuged. The blood 
centrifugation allows cellular elements and plasma separation according to different 
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specific weight. The patient’s plasma collected is discarded and the patient receives his 
blood cells and substituent liquid (plasma or albumin) in the reinfusion step (fig.6). 
The duration of treatment (usually 2 to 4 hours) depends on the  volume to be 
exchanged and on the rate of exchange. The side effects PEX related may be due to 
extracorporeal treatment and to anticoagulant use. Anticoagulant can move into the 
circulation giving transient disturbances due to hypocalcaemia. Moreover the use of 
fresh frozen plasma as a fluid-replacement, exposes the patient to anaphylactic or 
allergic reaction. 
 
b. Erytro Exchange: The exchange of erythrocyte is used for treatment of acute 
stroke and chest syndrome, a dramatic clinical conditions due to erythrocyte 
deformation and anemia of sickle cell anemia. The sickle red blood cells are unable to 
cross in the microcirculation and it causes the vascular occlusion and stasis. The blood 
transfusion, improves the anemia, but increases blood viscosity and hematocrit and 
increases stasis and vascular occlusion. The purpose of erytro exchange is to replace 
sickled with normal cells. In this way it's possible improve clinical symptoms without 
increasing blood viscosity, reduce the hemolysis and iron accumulation. The exchange 
is performed by erythrocyte cell separator: after collection, whole blood is centrifuged 
and separated by gradient centrifugation. The patient’s erythrocytes collected are 
discarded and the patient receives his plasma and compatible normal erythrocytes Any 
procedure exchange one red cell volume corresponding to. 15-20 ml / kg. Thus, 
average weight patient (i.e: 60 kg) exchanged1200 ml of concentrated red blood cells 
corresponding to 4 RBCs units. RBCs transfused must be of recent production (no 
more than 2 weeks) and produced by aphaeresis, preferably. Each RBCs unit is 
matched for ABO, Rh and Kell antigenic systems (perfect match is ABO-D, Rh, Kell, 
Duffy, MNSs) and performed compatibility tests. This type of therapy and the number 
of sessions to be repeated, exposes the patient to the risk of alloimmunization, the 
formation of antibodies directed against non-self erythrocyte minor antigens untyped 
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and not observed for RBCs selection. So, the alloantibodies are always sought after 
and their presence or their immune memory is always considered to assign units of 
RBCs. 
 
c. Plasma treatment: it's the plasma filtration with semi-selective (cascade 
filtration) or selective (adsorption) techniques. The patient's plasma, separated  and 
treated, is returned to the patient without pathogenic molecules. This reduces the risk 
of anaphylactic reactions to not self protein molecules, characteristic of plasma 
transfusion.  
The filtration techniques are: cascade filtration and adsorption. 
 Cascade Filtration or double filtration: It's a technique of physic plasma 
separation obtained by centrifugation extracorporeal into cell-separators. Two series 
filters are used. The first separator filter is formed by high cut-off micro pores (270 to 
400 microns) for blood cells separation (erythrocytes, leukocytes, platelets). The 
second filter or fractionation filter is formed by low cut-off micro pores (70 microns) 
for molecular weight separation. The excessive high weight molecules (immune 
complexes, IgM, fibrinogen, LDL-C) may be dangerous in many disease. So the 
cascade filtration consent to eliminate the high weight molecules and to give back to 
the patient the plasma containing lower weight molecules (electrolytes, substances 
with a low pm, albumin) and the cells separated and collected by first filter (RBC, 
WBC, PLT) (Fig 7). The filtration procedure consent to treat 2-3 liters of plasma (40-
50 ml/kg) (Kardaş et al 2012) 
 Adsorption: Aphaeretic technique to remove plasma pathogenic molecules by 
columns adsorbed with specific ligands. The adsorption can be chemical, 
immunological or physic. After collection, patient's whole blood is separated by 
centrifugation or high molecular weight filtration; so are obtained plasma and cellular 
blood components (RBC, WBC, PLT). The plasma is adsorbed on specific columns 
containing selective ligands specific to treat pathology. When the plasma is deprived 
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of pathogenic molecules, it is collected and rein fused to the patient with cellular 
component. This method is highly selective and acts on the pathogenic mechanisms of 
disease. The true limits relate the columns costs: in relation to substance plasma 
concentration and to ligand used volume, columns saturate quickly. Therefore, usually, 
it is preferable to treat disease with other treatment options, with less expensive 
techniques, limiting the use of adsorption in a few clinical cases. In particular, this 
technique is used for the selective removal of LDL low density lipoprotein (LDL 
apheresis). The LDL apheresis columns contain anti lipoproteins apo B100 antibodies 
obtained to sheep serum and adhering to a solid sepharose matrix. In general, the 
ligands are chemical (dextran sulfate, acrylic acid, activated carbon, resins 
polyanionic, heparin), physic-chemical (phenylalanine, tryptophan and styrene-
divinylbenzene) or biological (protein A for the adsorption of IgG). The selection of 
column type depends on treated pathology. The treatment of chronic liver failure, 
primary biliary cirrhosis, decompensated cirrhosis and hyperbilirubinemia pre and post 
liver transplant consist in bilirubin (conjugated and unconjugated) and bile acids 
adsorption. Some autoimmune diseases (multiple sclerosis sistemic sclerosis, SLE, 
RA, Guillain-Barre syndrome Fischer) can be treated with physic-chemical columns 
containing phenylalanine, able to absorb antibodies and immune complexes or in some 
cases (Guillain-Barre and Fischer Syndrome, chronic demyelinating polyneuropathy) 
with columns containing tryptophan able to remove IgG and ACh-R-Ab 
 
d. Therapeutic cytapheresis: This technique is mainly used for the selective cell 
depletion of leukocytes, erythrocytes or platelets. It removes excess pathogenic cells 
responsible for serious clinical symptom. Once, this effect was obtained only with the 
therapeutic phlebotomy, that removing the whole blood, depriving the patient also 
elements useful for his health. In the 60's were introduced cell separators based on 
gradient centrifugation of blood cells. So, it's possible to separate whole blood into its 
cellular components and plasma using the different sedimentation coefficients  when 
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the cells are subjected to an appropriate centrifugal force (G-force). In this way, can be 
deleted only the pathological cells in excess and the rest of the blood can be re infused 
to patient. The main application areas are hematological diseases: the platelet 
apheresis therapy is performed in cases of severe thrombocytosis to reduce the risk of 
thrombosis. (Russi et al 2008).The therapeutic leukapheresis is used to remove buffy 
coat in high risk of bleeding thrombosis and pulmonary leukostasis hematological 
malignancies,. The erytroapheresis therapy is used to restore the correct values of 
haematocrit (necessary to correct hyperviscosity) in patients with primary or 
secondary erythrocytosis symptomatic. However, if therapy depletion is not 
accompanied by appropriate drug therapy, has only temporary effects. A particular 
type of therapeutic cytapheresis is photoapheresis therapeutic. In the last 20 years, this 
technique has revolutionized the follow-up and outcome of patients with GVHD. It is 
a technique of therapeutic leucapheresis in which the patient's white blood cells 
(collected by centrifugation), are treated with 8 methoxypsoralen, irradiated with UVA 
and then reinfused to the patient. This cell manipulation triggers apoptosis of 
leukocytes that activates dendritic cells, modulating the effects of GVHD and 
monitoring the effects of rejection of solid organ transplantation (Bruserud et al 2014) 
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Fig 6. Plasma Exchange treatment diagram and particular of bowl blood centrifugation (up). 
Modern cell separators used for aphaeresis procedures (down) 
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Fig 7 Plasma treatment double filtration diagram and particular of filtration (up). 
  Modern cell separators used for plasma filtration (down) 
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1.2.2. Regenerative medicine 
Regenerative medicine can be considered  the final frontier for the treatment of 
many diseases and represents a new philosophy to approach tissue/ organ degeneration 
by biological regeneration. In particular it is possible to use blood products for not 
transfusion use and their ability to initiate the regenerative stimulus and tissues repair. 
In the 70s, for the first time, fibrin glue was produced and used to accelerate tissue 
repair processes in surgery. In the 80s, David Knighton developed in vitro a platelets 
stimulation technique by thrombin solutions for collection of a rich growth factors 
supernatant  topically applied in the gel form.  
The use of not transfusion blood components begins in 1998 with the first 
publication of Marx et al. on the use of platelet concentrates in dental surgery
 
(Marx et 
al 1998). With the first clinical successes, interest has extended to other medicine and 
surgery fields and several methods of production and other clinical indications have 
been proposed. 
This gel is able to stimulate the skin ulcers repair and to accelerate tissue 
regeneration in a variety of clinical and aesthetic settings:
. 
platelet concentrate is a 
source of growth factors and is used both in liquid form that enabled, as a promoter of 
damaged tissues regeneration (Coppola 2004; Knigthon 1990). 
The platelets growth factors (GFs) are capable of several function: to induce 
mesenchymal cells replication and chemotactic action to the inflammatory cells 
(polymorphonuclear leukocytes, monocytes, and macrophages), to proteases release 
from other cells activating tissue remodeling. (Rughetti 2006) Therefore, platelet are 
not only the protagonists of the haemostatic process, but also has a key role in 
inflammatory process (because they have high concentrations of pro-inflammatory 
chemokines or immuno- modulatory), in antimicrobial defense (since the -granules 
are rich in "protein microbicide platelet "-CXCL4 , thymosin - β4 , derivatives of 
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CXCL7- PBP ,CTAP - III ,NAP- 2 and CCL5 -6 and complement proteins), in cell 
replication (mitogenesis), in angiogenesis and in modulate tissue regeneration. 
(Gallagher 2007; Lucarelli 2003) 
Nowadays, there are many literature's studies on the use of platelet gel and growth 
factors (GFs) contained in the platelets's α-granules (PDGF, TGF-β, EGF, FGF, 
VEGF, IGF-1). 
Platelets activated produce angiogenesis factors (VEGF, PDGF, FGF, EGF, HGF, 
IGF) to promote vascular wall permeability, endothelial and fibroblasts cells 
recruitment, growth and proliferation. (Tang et al  2002; Kisucka et al 2006; Nurden 
et al 2008) 
As opposed, platelets inhibit angiogenesis by endothelial cells apoptosis (TSP-1 is 
a potent endothelial cell proliferation inhibitor; CXCL4 prevents binding of VEGF to 
its cell receptor and interferes with the mitogenic effect of FGF and other proteins 
such as angiostatin, endostatin and TIMP -1 and -4). (Jimenez et al 2000; Bikfalvi 
2004) 
Therefore, the use of platelet gel is effective in the treatment of various diseases 
(skin ulcers, reduction of inflammation, increased angiogenesis, stimulation of 
granulation tissue). Stimulation on bone regeneration and soft tissue, has led to its use 
in maxillofacial surgery, in odontostomatology (implants, sinus lift, cleft palate), in 
orthopedics and traumatology (soft tissue injuries, nonunion, loss of substance bone 
following trauma or removal of cysts), in ophthalmology (corneal epithelial injury), in 
cardiac surgery (sternal wound dehiscence) and in other disciplines in which is 
appreciated effectiveness, ease of use and lack of reactions or events adverse. 
Numerous evidences have tested gel platelet efficacy on skin ulcers repair (traumatic, 
vascular, neuropathic, diabetic, osteomielitic, decubitus), on orthopedics disease 
(osteosynthesis, pseudoarthrosis, osteotomies, joint replacement, infiltration intra-
articular), on maxillofacial surgery, on stomatology (ablative interventions of the 
maxillofacial region, mandibular reconstruction, maxillary sinus), on ophthalmology 
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(topical corneal lesions), on plastic surgery and cosmetic medicine. (Champion et al 
1998; Misso at al 2006; Bryne et al 1991; Holloway et al 1993)
. 
According to the 
Standards of Transfusion Medicine, allogeneic or autologous not transfusion blood 
components, can be used topical, on skin or mucosal surfaces; for intra-tissue 
infiltration; local application in surgical sites, alone or with the addition of non-
cellular biological material (e.g. bone tissue bank) or with medical devices. These 
products must be produced by a Transfusion Medicine Laboratory and must meet the 
criteria for the request, assignment, delivery and haemovigilance and guarantee the 
identification and traceability of the donor and recipient. 
In particular, can be produced:  
a. Platelet concentrate (allogeneic or autologous): prepared from whole blood or 
multicomponent apheresis or blood sampling in dedicated device. Can be used fresh 
or frozen and contained  defined and variable volume according to the type of use. 
In conjunction with the production of platelet concentrate, can be produced 
thrombin used as platelets activator. 
b. Platelet gel: (allogeneic or autologous).it is obtained from platelet concentrate 
activated at the site of application or  in the production phase and delivered ready 
for use, fresh or frozen. 
c. Autologous serum eye drops. It is produced from a blood sample in which the 
coagulation is activated and then separate the serum component. 
d.  Platelet concentrate eye drops. It is produced from autologous platelet 
concentrate  
e. Fibrin glue. It is a topical biological adhesive which mimics the final stages of 
coagulation: from the fibrinogen chain thrombin splits into peptide A and B to form 
a monomer, which polymerizes to form fibrin clot at the site of application. Fibrin 
glue is a adjunct treatment in numerous surgical fields and is beneficial involve a 
high risk of postoperative bleeding or the leakage of air, blood and other fluids. The 
structural composition of fibrin and the binding of fibrin to cells and proteins 
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determines the wound healing process. This represents an ideal delivery vehicle for 
additional cells for the treatment of chronic wounds. 
 
1.2.3. Stem cells 
At the beginning of the 20th century, Alexander Maximow says that in the 
peripheral blood there was a small number of circulating cells that has been able to be 
pluripotent and he called these cells "gemeinsame Stamzellen". 
After several decades of attempts, the existence of these stem cells, was confirmed, 
Hematopoietic Stem Cells (HSC), cells with the capacity to self renew and the 
potential to generate mature specialized cell types; they are able to differentiate into 
cell types within the tissue in which they reside (“stem cell plasticity”). When a stem 
cell divides, the daughter cells can either differentiate in a specialized cell or self 
renew to remain a stem cell, so ensuring that the pool of stem cells is constantly 
replenished; this is a necessary physiological mechanism for the maintenance of the 
cellular composition of tissues and organs in the body. (Jansen et al 2005) 
The general characteristics of stem cells can  be classified as totipotent, pluripotent 
and multipotent.  
Totipotency is the ability to form all cell types; totipotent cells can basically form 
the whole organism because they have unlimited capability. 
Pluripotency is the ability to form several cell types but not the whole organism. 
There are four classes of pluripotent stem cells: embryonic stem cells, embryonic germ 
cells, embryonic carcinoma cells and the adult progenitor cells from bone marrow. 
Multipotency is the ability to generate a limited range of differentiated cell lineages 
appropriate to their location, e.g. blood stem cells which give rise to red blood cells, 
white blood cells and platelets. (Durand et al 2005) 
HSC transplantations started in the late 1940’s with experiments in mice. Starting 
in the late 1950’s several groups tried to apply these concepts to the treatment of 
patients with leukemia, and in the late 1970’s these concepts gained acceptance: 
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allogenic or autologous bone marrow as source of stem cells, was used for all clinical 
transplantations ; while, at that time ,peripheral blood as a source of stem cells was 
still considered inadequate to permanently reconstitute hematopoiesis. (Jansen et al 
2005) 
The best studied adult stem cell is the hematopoietic stem cell (HSC). 
The interest of transfusion medicine for HCS, concern the possibility of collecting 
hematopoietic stem cell and transplant in recipients for the treatment of several major 
blood diseases. HSC transplantation is an effective therapy for a wide variety of 
neoplastic diseases, in addition to congenital and autoimmune disorders. 
The HCS donors can be the recipient (autologous donor) or, more frequently, a 
related or unrelated HLA compatible (allogeneic donor).  
In autologous HSC transplantation, chemotherapy and/or radiation are 
administered to the patients, so, prior to HSC transplantation, patients undergo 
harvesting of their hematopoietic cells from bone marrow or from peripheral blood.  
The allogeneic donors, typed according to international standards (IBMDR, EFI, 
JAICE), are inserted in international directors (donor banks) and made available for 
donation only after research of "perfect" HLA match with the recipient. (Shizuru 2005) 
The HCS can be obtained by removal of bone (classic donation in use since the 
60s) or peripheral blood after adequate "mobilization" from bone HCS with growth 
factor G-CSF (10 µg/kg sc) and collecting in apheresis or by placental/cord blood.  
Before 1990, almost all HSCs transplantations were bone marrow-derived. At the 
end of the 1980’s the first case of allogeneic peripheral blood stem cell (PBSC) 
transplantation was reported. Since the donor was not mobilized by cytokines, he 
underwent ten aphaeresis to harvest a sufficient stem cell number. Engraftment was 
successful. In 1988, the ability of granulocyte-macrophage colony stimulating factor 
(GM-CSF) and granulocyte colony stimulating factor (G-CSF) to mobilize HSCs to 
the blood stream was documented. Mobilization with either chemotherapy and/or 
growth factors injection may result in an efflux of HSCs out of the bone marrow into 
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the blood and lead to a concentration of HSCs in the peripheral blood that equals or 
exceeds the concentration in the bone marrow itself. An HSC-enriched cell fraction 
can then be collected by aphaeresis from the blood. In 1995, the first series of GCSF-
mobilized stem cell allogeneic transplantations was published. (Vaglio 2005) 
The amount of HCS changes according to the type of source: the increased amount 
of HCS is contained in the bone (up to 3%), followed by the cord blood (up to 1%) 
and finally from the peripheral blood (up to 0.1%). However, today the most common 
sampling is from peripheral blood because, after stimulation with G-CSF, the amount 
of HCS increases considerably exceeding the amount contained in the bone and is less 
invasive  
Autologous and allogeneic HSC transplantations are used, depending on donor 
availability and the type of treated disease. 
The principle behind allogeneic HSC transplantation differs, as do the spectrum of 
diseases treated and the potential benefits and complications.  
Compared to autologous HSC, allogeneic HSC transplantation has a higher 
incidence of treatment related morbidity and mortality, particularly because it contains 
immune cells that can respond against host-specific antigens and causes the syndrome 
called graft-versus-host disease (GVHD). Despite the prophylaxis with 
immunosuppression, 20-30% of allogeneic HSC transplantation patients develop an 
acute form of GVHD, and 50% develop a chronic form of the disease. If we put 
together the risk of GVHD, immunosuppression, and the potential failure engraftment, 
the transplantation-related mortality for an allogeneic HSC transplantation is 10-15%. 
(Vaglio 2005) 
Under standard conditions, donors and recipients are matched at the genes of the 
human leucocyte antigens (HLA). 
However, identify suitably matched related or unrelated donors can be difficult in 
some patients and alternative sources of stem cells have been explored. Cord blood 
provides a readily available source for such patients. The collection of cord blood cells 
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is relatively easy and the risk of severe acute graft-versus-host disease (GVHD) is 
lower.  
Data accumulated over the past several years have demonstrated that cord blood is 
an accepted alternative source for hematopoietic stem cells in children. It offers many 
practical advantages such as: 
1) absence of risk for mother and newborn; 
2) relative ease of procurement and availability (as stored cord blood cells are fully 
tested and HLA-typed, they are available for immediate use); 
3) potential reduced risk of GVHD. 
While the clinical data is encouraging for pediatric patients, cord blood use can be 
more problematic in adult patients since the limited number of hematopoietic 
progenitors and the collection can occur only in a single occasion. Nevertheless cord 
blood transplantation has recently been explored in an increasing number of adult 
patients. The reason is that, while the total numbers of mononuclear cells are limited, 
the progenitor content and the proliferative potential of cord blood cells are high. So 
some protocols are now available to attempt to use cord blood as an alternative source 
of hematopoietic stem cells for allogeneic transplantations for adult patients too. 
(Tokiko et al 2014) 
The possibility to purify and expand HSCs has recently led to the implementation 
of non-hematological clinical trials, aimed at developing tissue repair protocols in 
chronic-degenerative disorders as Alzheimer’s disease, Parkinson’s disease and other 
neurological disorders; it has opened up new and unexpected therapeutic perspectives 
also in the treatment of nephropathies (kidney transplantation), and other diseases 
involving liver, brain and heart. For example the infusion of autologous bone marrow 
stem cells in the coronary artery has been proposed for regenerating the myocardium 
after ischemia. 
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1.2.4 Blood groups and molecular biology  
Molecular biology has been extensively applied in characterizing the genetic basis 
of blood group systems and developing clinical diagnostic tools for 
immunohematology and transfusion medicine. The discovery of the molecular basis of 
most red cell antigens, combined with advances in molecular testing, have paved the 
way for the use of genotyping to predict the red cell phenotype.  
Genotyping offers many advantages over serologic testing of recipient blood with 
the primary benefit to predict the blood group phenotype in situations that do not 
permit this serologically. For example, alloantibodies develop in approximately 2-4% 
of people after transfusion, with a higher rate (20-40 %) among chronically transfused 
patients such as those with sickle cell anemia or thalassemia. Using hemagglutination 
to phenotype red blood cells from a person with alloantibodies can be complex and the 
results can be difficult to interpret. In these cases, genotyping helps to predict the red 
cell antigen type and provides a more complete characterization of the blood type. 
(Flegel 2011; Denomme et al 2008; Hilleyer et al 2008; Westhoff 2008; Avent 2009) 
Given the large number of known genetic events that silence or weaken the 
expression of antigens encoded by an allele, it will be a long time before all relevant 
nucleotide changes are revealed for all blood group systems in all ethnic groups. For 
these reasons, care must be taken when using molecular methods as the serological 
problem may involve the inheritance of a null allele, a hybrid gene or a new variant.  
In this context, the analysis of blood group variants is very important to predict a 
red cell phenotype using molecular methods. 
Today, typical clinical applications for blood group genotyping are performed for 
RH, ABO and other protein based blood group systems.  
The methods for ABO and RH based on modular PCR with sequence specific 
priming (PCR-SSP) brought about the first commercial blood typing kits, which are 
still available today.  
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Genetics of theABO 
ABO was the first blood group system to be described and applied to clinical 
practice. While ABO is also the first blood group system defined at the gene level, the 
earliest clinical genotyping for any blood group system was published on RHD (Flegel 
2013).  
The genetics of the ABO blood group system was first described in by Bernstein 
1924 as consisting of a set of three allelic genes, A, B and O, at a single genetic locus. 
In 1976, the chromosomal assignment of the ABO locus was mapped to the region 
9q34.2 at the distal end of the long arm of chromosome 9.  
The genes direct the occurrence and location of A and B antigens; however, the 
products of the genes are not the antigens themselves, but the enzymes 
(glycotransferases) that contribute to the production of the A and B antigens.  
The genes that direct A and B antigen development are at three separate loci: ABO, 
Hh, and Se.  
Three common alleles (A, B and O) are located at the ABO locus on chromosome 
9 at 9q34.1-q34.2, and the genes at the other two loci, Hh and Se, are closely linked on 
chromosome. Hh and Se loci each have two recognizable alleles, one of which has no 
demonstrable product and is considered an amorph. (Flegel 2013). 
The active allele at the H locus, H, produces a glycosyltransferase that acts at the 
cellular level to form the antigen on which A or B is built. The amorph, h, is very rare 
with a prevalence of 0.004 percent. (Flegel 2013). 
The Se gene is responsible for the expression of H (and indirectly responsible for 
the expression of A and B) on the glycoproteins in epithelial secretions such as saliva. 
Secretors inherit the Se gene; and their secreted glycoproteins express H, which can be 
converted to A and/or B antigen if the A and/or B gene is/are also present. The amorph 
is called se.  
The H locus encodes a fucosyltransferase that produces the H antigen on RBCs, 
which is an essential precursor to the ABO blood group antigens. 
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The A gene, encodes a glycotransferase that bonds a-N-acetylgalactosamine to the 
D-galactose end of the H antigen and produces the A antigen.  
The B gene, similarly, determines the presence of the B antigen by encoding a 
glycotransferase that joins a-D-galactose to the D-galactose terminal sugar of the H 
antigen, creating the B antigen.  
The O gene does not produce a functional protein; and in the heterozygote with an 
A or B gene, has little influence on the expression the A or B antigen. Thus, 
phenotypically, the O gene is recessive, and the A and B genes are codominant (Table 
2). A and B genes differ from one another by seven single-base substitutions, which 
result in four possible amino acid substitutions (at positions 176, 235, 266 and 268) in 
the protein sequence of the A and B transferases. All variant A and B phenotypes, 
which have a weaker expression of the A and B phenotypes (subgroups), have been 
shown to be mutations of the A or B gene, resulting in less effective transferase 
production. Multiple polymorphisms have been shown in the non coding regions of 
genomic sequences of the ABO alleles, and these sequence variations can affect A and 
B antigen expression resulting in weak ABO phenotypes. A single base deletion in the 
O allele shifts the codon reading frame and is responsible for the loss of activity of the 
A glycotransferase. (Flegel 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Genotypes of the ABO Blood Groups 
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The molecular mechanism influencing the ABO alleles gene expression are three 
groups: (i) epigenetics: (ii) epistasis; and (iii) molecular genetics. Blood group 
antigens in general and the ABO antigens in particular are prime examples for 
researching such mechanisms in the era of genomics and for utilizing the knowledge 
in clinical applications. DNA methylation, as one of the epigenetic mechanisms, has 
been shown to occur in the ABO gene: hypomethylation of CpG islands in the ABO 
gene promoter was associated with the expression of the ABO antigens in cell lines 
(Yamamoto et al 2012).  
Second, epistasis, the modification of a phenotype of one gene by another gene, 
has been known in ABO since 1952 , when Bhende et al. showed in 2 patients and 
1donor that the ABO antigens were not expressed, because another gene product was 
lacking This other gene became known as H transferase along with its extensive allele 
polymorphism. (Kominato et al 1999).  
Third, molecular genetics mechanisms explain the vast majority of blood group 
antigens, caused by genetic variation in exons or in other parts of the gene. In fact, the 
single nucleotide deletion in exon 6 of the ABO gene resulting in the lack of A and B 
antigen expression and the phenotype blood group O, was the first example of a 
genetic variant shown in any blood group gene (Yamamoto et al 1990). Today, several 
hundred examples of genetic variations in exons are known to affect gene expression 
among the 33 blood group systems. Genetic variations in gene segments other than the 
exons, such as the promoter, 5' and 3' untranslated regions and the introns, are 
observed less commonly, yet are equally important. Current examples are a tissue 
(erythroid cell)-specific factor binding to the ABO promoter and an enhancer protein 
binding ABO intron 1, which control the expression of the ABO gene (Sano et al 2012) 
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Genetics of the RHD 
There are now 51 antigens within the Rh system and more than 200 alleles for the 
RHD gene alone. RHD zygosity has been resolved, epitopes have been mapped, and 
many D variants with altered antigens have been identified.  
Based on the homology of Rh polypeptides to the ammonia transporter AmpB, 
computational analyses have modeled the 3D structure of the RhD polypeptide to learn 
about additional potential functions of Rh polypeptides
 
.The reason for this interest is 
that RHAG, a gene located on chromosome 6 (6p11–p21), shares an identical exon 
structure and major regions of sequence identity with RHD/RHCE (Carton et al 2001).
 
 
To date, the function of RhD and RhCE appears associated with membrane 
integrity, and possibly transport of gases like carbon dioxide. RhAG may contribute to 
gas exchange across the plasma membrane, and its mutations are associated with 
hereditary stomatocytosis (Marini et al 2000). Thus, expression of Rh polypeptides 
and associated proteins is complex, and molecular discoveries have broadened our 
understanding of this important blood group system. 
Regard to genetics aspects, RH is a bigenic locus comprising RHD and RHCE 
positioned in a tail-to-tail orientation toward the end of the short arm of chromosome 1 
(p34–36). Another gene, SMP1, is interspersed between both RH genes in close 
proximity to the 3’ end of RHCE. Identification of the single murine equivalent in the 
mouse genome project provided evidence that RHCE evolved from the ancestral RH 
on the basis of the position and orientation of murine genes in the region (Fig.8). 
Therefore, RHD arose from a duplication event that predates modern humans. 
(Blancher 2000)
  
During the duplication event, and possibly associated with its cause, two 
approximately 9,000 base-pair-long homologous repeat sequences, termed Rhesus 
boxes, were likely introduced that flank the RHD gene in the genomes of modern 
humans. RHD was lost from the genome through unequal crossing over involving the 
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upstream Rhesus box and downstream Rhesus box (Fig. 9), an event that may have 
occurred more than once.  
The tail-to-tail orientation may facilitate the large number of alleles; the 
identification of corresponding nucleotides in both genes suggests that most hybrid 
alleles arise through gene conversion events (Fig. 10) 
RHD and RHCE share regions of identity, with the translated RhD polypeptide 
differing at up to 36 amino acid positions depending on which RhCE polypeptide it is 
compared. Both Rh polypeptides comprise 12 transmembraneous protein segments 
and 6 extracellular /intracellular loops (Fig. 11).  
Historically, serologic studies classified the D antigen into six major categories 
(DII through DVII, with DI being obsolete). Three epitope models were proposed 
comprising 9-epitopes or 37-epitopes or the combination of both based on the 
serological reaction pattern of more 80 monoclonal anti-D antibodies. (Lomas et al 
1989; Scott 1996).  
Many variants express altered D antigen, but no absolute correlation exists 
between phenotypic expression and clinical relevance of RHD alleles. RHD alleles 
have been classified on the basis of their phenotypic relationship to the molecular 
variation: partial D, weak D types, DEL, and nonfunctional alleles.(Daniels 2002; 
Reid et al 2003). 
 
More than 200 RHD alleles have been reported and may be grouped 
according to serological and molecular features (Table 3).  
The classification of partial D variants is based on the premise that certain amino 
acid substitutions on an extracellular loop affect linear D epitopes or, more often, the 
3dimensional conformation of that loop. Many partial D are identified using 
monoclonal antibodies that target specific domains or loops on the surface of the 
erythrocyte.  
The D categories (DII to DVII) represent a subset of all partial D. DII and DVII are 
caused by single extracellular amino acid substitutions, while DIII, DIV, DV, and DVI 
are caused by RHD-CE-D hybrid alleles and comprise several subtypes each. The 
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classification as partial D is of clinical relevance because carriers often produce anti-D 
upon exposure to the normal D antigen (Rouillac 1995). 
However, for many partial D, anti-D immunization events are apparently rare, and 
for several partial D there has been no observation of any patient with anti-D so far. 
These facts are compatible with the conclusion that carriers of several distinct partial 
D may be at a very low or no risk of anti-D immunization. 
 A weak D type is a variant of the RhD protein that comprises an amino acid 
substitution located in the transmembraneous or intracellular segments and expresses a 
reduced amount of D antigen (generally less than 5,000 D antigens per RBC). A group 
of 16 distinct weak D types were described originally, but the total number of weak D 
types including their subtypes now exceeds 80.  
The substitutions are thought to cause folding problems during integration of the 
protein into the RBC membrane, which can impede protein integration, affecting 
palmitylation or anchoring of the polypeptide to the RBC cytoskeleton. Hence, the 
amount of D antigen expressed on the RBC surface is quantitatively reduced, but the 
D antigen itself remains, by-and-large, qualitatively unchanged. Therefore, the normal 
D antigen is not usually immunogenic (Wagner et al 1999; Gane et al 2001). 
Like the mentioned exception for several partial D that cannot be immunized, there 
is an exception for some weak D types. Anti-D immunization in weak D carriers is 
rare, but there are exceptions: examples include weak D type 15, weak D type 4.2, also 
known as DAR, and weak D type 7. 
The weak D types 1, 2, 3, and 4.0/4.1, which are the most prevalent in any 
European and Caucasian population, represent more than 95% of all weak D types. To 
date, more than 10 years after their molecular description, the literature has not 
documented any carrier of weak D types 1 through 4.1 being alloimmunized and 
producing allo-anti-D (Ansart Pirenne et al 2004; Legler et al 2001).
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Those observed produce low titer antibodies of autoantibody nature. The 
observation that the common weak D types fail to make allo-anti-D is particularly 
relevant in the prevention and management of anti-D alloimmunization in pregnancy. 
 A very weakly expressed D antigen is called DEL (formerly D) because it was 
originally detected only if anti-D adsorbed and then eluted from RBCs. 
Typically, RBCs with DEL express 200 or fewer copies of the D antigen per RBC. 
The most common DEL is caused by the RHD(K409K) allele harboring the C1225A 
nucleotide substitution in exon 9. Because it is very prevalent in D negative Asians, it 
has been dubbed the “Asian type” DEL. This substitution is a silent single nucleotide 
polymorphism (SNP), the amino acid lysine (K) at position 409 remains unchanged. 
However, the substitution causes missplicing mRNA such that the complete full 
messenger mRNA has never been documented and at most represents a very minor 
form of transcript for translation. (Wagner et al 2001) 
Even combined, all DEL phenotypes are rare in Europeans. Up to 30 % of 
seemingly D-negative East Asian people carry the DEL RHD(K409K), but other DEL 
alleles are also more frequent in Asia than in Europe.  
DEL is of interest worldwide because of its potential to cause anti-D 
alloimmunization when DEL-positive blood donors are inadvertently labeled as D 
negative. 
In addition, DEL alleles can cause genotype-phenotype discrepancies and should 
be taken into consideration when fetal blood group genotyping methods depend on the 
ethnicity of the parents. The fetal inheritance of DEL would not be considered a risk of 
hemolytic disease of the fetus and newborn (HDFN). (Flegel 2005) 
 The most common D negative haplotype in all populations is caused by the 
deletion of the whole RHD gene with the concomitant presence of the hybrid Rhesus 
box (Fig. 9). However, other D negative haplotypes exist.  
Some individuals who are D negative can harbor a nonfunctional RHD allele. One 
of the first nonfunctional RHD alleles was termed RHD pseudogene (RHDψ).  
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Both nonfunctional alleles occur rather frequently in African populations. Less 
common D negative alleles are caused by a host of different hybrid RHD-CE-D alleles 
or nonsense and frame shift mutations. It is important to note that the distinction 
between apparent D negative and DEL phenotypes by serology may be somewhat 
arbitrary. But the clinical significance is not: DEL blood transfused to D negative 
transfusion recipients is immunogenic, and the common “Asian type” DEL is not 
prone to making anti-D after its carrier is transfused with normal D positive RBC 
units. Therefore, in Asian populations, in whom D negative blood is rare, identifying 
DEL transfusion recipients (approximately 1/3 of all serological D negative) could 
significantly reduce the demand for Rh-negative blood (Daniels et al 1998; Singleton 
et al 2000)
 
 Rh null. The lack of both RhD and RhCE proteins may be caused by the 
inheritance of two nonfunctional RHCE alleles in the background of an RHD deleted 
haplotype. This constellation gives rise to the amorph type Rh  phenotype (lack of any 
Rh protein), in which neither D nor CE antigens are expressed null. Alternatively, 
because the expression of either Rh protein requires the presence of RhAG for 
appropriate assembly on the RBC membrane, defects in RHAG alleles cause the lack 
of both RhD and RhCE proteins. This biological background explains why defects in 
RHAG alleles cause the regulator type Rh phenotype (lack of expression of Rh 
protein), in which D and CE antigens may be undetectable but are in principle 
expressed .Rh null alloimmunization in pregnancy can be extremely difficult to 
manage in the setting of HDFN, largely due to the lack of compatible allogenic blood. 
Maternal blood has been used as a source of blood for the fetus and neonate (Kato 
Yamazaki et al 2000) 
 RhCE variants. Partial antigens have been reported for the common RhCE 
antigens; C, c, E, and e, although several RHCE alleles have been characterized and 
many other alleles may exist. As with partial D, carriers of partial CE antigens can 
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make antibodies to epitopes that are missing on the variant RhCE protein. Unlike 
RHD, RHCE is not often deleted. 
Therefore partial CE antigens are less obvious from serology, because they are 
covered by the regular RhCE protein from the second chromosome. Few people carry 
these variants, which is one reason that alloimmunization is uncommon. The clinical 
relevance of RhCE variants may be more appreciated once molecular analysis allows 
deeper insight into their associated immunization events, like, for instance, in sickle 
cell disease (SCD) patients, in pregnancies, and in chronically transfused patients 
(Tournamille et al 2010). 
60 
 
 
 
 
 
 
 
 
 
 
Fig. 8: Duplication of the RH gene and loss of the RHD gene:The ancestral configuration is shown 
as represented by the RH gene locus in mouse. The single RH gene is in close proximity to the three 
genes SMP1, P29-associated protein (P), and NPD014 (N). A duplication event introduced a second RH 
gene in reverse orientation between N and SMP1. At the two break points in front and behind the RHD 
gene, DNA segments of approximately 9,000 base pairs (bp) occur. Both DNA segments are flanking 
the RHD gene and dubbed ”upstream Rhesus box“ and ”downstream Rhesus box“. In the RHD positive 
haplotype, the RHD gene may have been lost by a recombination event (see Fig. 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9. RHD deletion An unequal crossing over event between an upstream Rhesus box and a 
downstream Rhesus box caused the RHD deletion. If one of the two crossed-over chromosomal threads 
are resolved, an RH gene locus results that lacks the RHD gene completely and harbors a hybrid Rhesus 
box. 
61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10. RHD/RHCE hairpin formation 
The schematic diagram depicts the mechanism of gene conversion at the Rhesus gene locus on one 
chromosome. (i) The RHD and RHCE genes are inversely orientated, which is typical for clustered genes. (ii) A 
hairpin formation of the chromosome would generate the close proximity of homologous segments in identical 
orientation. This structural feature is generally instrumental in gene conversion events in cis. (iii) Resolving the 
hairpin yields an RHD-CE-D hybrid gene structure, many of which have been observed to date at the RH gene 
locus.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.11. Model of Rhesus proteins in the red blood cell membrane 
Both Rhesus proteins comprise 417 amino acids, shown here as circles. Mature proteins in the membrane lack 
the first amino acid. The amino acid substitutions that distinguish the RhCE from the RhD protein are marked in 
yellow, with the 4 amino acids that code for the C antigen in green and the one that codes for the E antigen in black. 
The single amino acids substitutions which code for partial D are in blue, and those that code for weak D are in red. 
The mutations that had been identified at the Ulm Institute since 1999 are in light blue and orange. The 
extracellular Rh vestibule is depicted by the inverted black arc and bordered in part by amino acids of loops 3 and 
4. The nine exon boundaries in the RHD cDNA, as reflected in the amino acid sequence, are indicated by black 
bars. 
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Table 3. Representative molecular changes in RHD alleles expressing distinct phenotypes of the D 
antigen 
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2. AIM OF THE THESIS 
 
The transfusion medicine history transformed its connotations through the 
millennia: from magic and esoteric practice of the ancient peoples, becomes today a 
fascinating scientific reality with multiple areas of action. 
The improvements of the last decades have created many fields of interest to the 
scientific community and radically changed the Blood Transfusion Service work.  
As witnessed by the numerous scientific sessions of the national and international 
conferences in recent decades (SIMTI, ISBT), together the historical transfusion 
activities involving the processing and banking blood, there is a strong interest in new 
activities able to open new and avant-garde borders in public health. 
The scientific discoveries and technologic advances that in the last 50 years have 
transformed transfusion medicine and blood banking are reported in table 4: 
 
 
 
Transfusion Medicine Improvements 
 Apheresis technology 
 Morrow and hematopoietic stem cells 
 RBC antigen and alloantibodies 
 The role of WBC 
 Plt and neutrophil antigens and antibodies 
 Volunteer blood donors 
 Blood safety 
 Hematopoietic growth factors 
 Plasma derivatives 
 Blood utilization and managements 
 Blood groups and Molecular Biology  
 
Table 4. Transfusion Medicine Improvements: key scientific discoveries and technologic 
advances in blood banking and transfusion medicine 
 
 
Thus the aim of my PhD was investigate knowledge focusing on molecular and 
cellular basic and applied aspects of Immunohematology and Transfusion Medicine. 
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Regard transfusion medicine, the application aspects related the transfusion 
approach to Moschcowitz syndrome (TTP or thrombotic thrombocytopenic purpura) 
and the role of regenerative medicine in osteoarticular injury.  
The first was a pathophysiological and clinical study of four clinical cases of 
patients affected by TTP and treated with plasma exchange, in the light of the 
therapeutic role of plasma therapy in this syndrome and the most recent 
etiopathogenesis knowledge of the disease. TTP is characterized by disseminated 
thrombotic microangiopathy associated with haemolytic microangiopathic anaemia. 
The pathogenesis is closely related to von Willebrand factor (VWF) since there were 
unusually large or ultralarge multimers of VWF (ULVWF) in the circulation of 
patients. Some severe forms of TTP seem to be related to ADAMST 13 plasma 
reduction. ADAMTS 13, a plasma reprolysin-like metalloprotease, cleaves VWF and 
attenuates arterial/venous thrombosis after oxidative injury. The more distal portion of 
ADAMTS-13 (TSP1 2–8 repeats and CUB domains) may function as a disulfide bond 
reductase to prevent an elongation of ultra-large VWF strings on activated endothelial 
cells and inhibit platelet adhesion/aggregation on collagen surface under flow. 
Remarkably, the proteolytic cleavage of VWF by ADAMTS-13 is accelerated by 
FVIII and platelets under fluid shear stress. A disruption of the interactions between 
FVIII (or platelet glycoprotein 1ba) and VWF dramatically impairs ADAMTS-13-
dependent proteolysis of VWF in vitro and in vivo. These results suggest that FVIII 
and platelets may be physiological cofactors regulating VWF proteolysis. Finally, the 
structure–function and autoantibody mapping studies allow us to identify an 
ADAMTS-13 variant with increased specific activity but reduced inhibition by 
autoantibodies in patients with acquired TTP. Together, these findings provide novel 
insight into the mechanism of VWF proteolysis and tools for the therapy of acquired 
TTP (Zheng et al 2013).  
The second application regards the role of regenerative medicine in osteoarticular 
injury, in particularly the effect of the platelet gel application in orthopedics was 
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studied. The platelets gel has a positive effect in tissue repair because effective 
accelerate the healing process of osteochondral, muscle, tendon and ligament lesions. 
In fact, platelets produce, store, and, if activated, release growth factors or GFs 
(VEGF, PDGF, FGF, EGF, HGF, IGF)) capable of several function as: inducing the 
replication of mesenchymal cells, exerting chemotactic action towards the 
inflammatory cells (polymorphonuclear leukocytes, monocytes, and macrophages), 
stimulating the release of proteases responsible for tissue remodeling. Therefore, 
platelet key role in the inflammatory process (due to high concentrations of pro-
inflammatory or immune- modulatory cytokines), in the antimicrobial defense (since 
the α- granules are rich 15 in "protein microbicide platelet", chemokines -CXCL4, 
thymosin-β4, derivatives of CXCL7- PBP, CTAP - III, 16 NAP- 2 and CCL5 -6 and 
complement proteins), in cell replication (mitogenesis), in angiogenesis and actively 
modulate tissue regeneration (Lucarelli et al 2003). 
The basic aspects of classical Immunohematology were related to the role of ABO 
antigens in aging and to the study of allelic variants of the antigen RhD. 
Regards the role of ABO antigens in longevity were reanalyzed data from a 
previous pilot study performed by our group and conducted on Sicilians centenarians 
(Vasto S, Caruso C, Castiglia L, Duro G, Monastero R, Rizzo C. Blood group does not 
appear to affect longevity a pilot study in centenarians from Western Sicily. 
Biogerontology. 2011 Oct;12(5):467-71). Centenarians are the best example of 
extreme human longevity, and they represent a selected population in which the 
appearance of major age-related diseases, such as cancer, and cardiovascular diseases, 
has been consistently delayed or escaped. The study of the long-lived individual 
genetic profile serves to identify the genes and the allelic variations influencing 
extended life expectancy. The aim of the study was tried to attempt a possible 
connection between the histo-blood group ABO and life expectancy, because the ABO 
phenotype was one of the first marker to be typed both for studying disease and ageing 
(Aird et al 1953; Murray 1961). The observed data showed a not-significant increase 
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of A1 allele in Sicilian centenarians. It is very interesting because literature shows that 
levels of serum soluble E-selectin (inflammatory marker of several diseases, 
cardiovascular included), are higher in O/O individuals, whereas a single nucleotide 
polymorphism in A1 allele is associated with low levels of these inflammatory 
markers. So, A1 allele increase in Sicilian centenarians, due to low levels of 
inflammatory mediators, mignt be related to the protection from adverse 
cardiovascular events. 
In the light of these data and of the evidences that the ABO blood antigens might 
play a key role in various human diseases, we reviewed the literature to study in deep 
the possible association of ABO group with age-related diseases and longevity taking 
into account the biological role of the ABO glycosyltransferases on some 
inflammatory mediators as adhesion molecules. 
The study of allelic variants of the antigen RhD was started at the Transfusion 
Service of AOUP “Paolo Giaccone” to perform the biomolecular analysis of all 
samples serologically identified as D variant or Du.  
The daily activity of serology laboratory, not distinguish an antigenic expression 
weak quantitative (weak D) from a qualitative (D Partial). This may be clinically 
significant in transfusion practice or prevention of HDFN.  
Therefore, after confirming the importance of bimolecular evaluation of donors 
and patients referred to our service transfusion, the project was approved by the 
President of SIMTI, Ph. Claudio Velati (fig 12) and was proposed to the transfusion 
services in the Province of Palermo to start an epidemiological study of allelic variants 
of RHD. The purpose of this analysis was to assess the impact of the phenomenon on 
the study population and map genotypes recurring. 
Considered the low incidence of samples RHD variant, the study is still in progress 
and is not yet complete recruitment of the samples. The partial analysis of the results 
obtained until now, has shown that the incidence of the D variant forms (0.12%) is 
slightly lower than described in literature for the general population (0.2-1%) and that, 
67 
 
unexpectedly, the sample observed shows a high prevalence of weak samples 5 and 
11, usually less common. This shifts the focus on genetic differences of the different 
ethnic groups to be found in the natural history of the Sicilian population. 
Furthermore, the observation of D variant compared to genotype RHCE highlights 
the constant association of forms Dvariant with a genotype RHCE that always 
determines the expression of C or E. These suggest that the RHD gene variant 
expressions may be related or dependent by trans position of RHE /C. These data give 
a new study perspective oriented to a of proteomic analysis. 
Another applicative aspect of transfusion services laboratory activities, concerns the 
HLA typing for stem cells and cord blood cells banking or for the study of platelet and 
erythrocyte reactivity. The new literature, data show a clear correlation between HLA 
and leukemia. In our Transfusion Service, the leukemia patients represent the largest 
sample of receiving blood and platelets and more exposed to the risk of 
alloimmunization. Then was made a literature review for preliminary correlation study 
between HLA and leukemia. 
HLA plays a central role in immune surveillance, and HLA polymorphisms may 
impact the ability of the immune system to identify malignant cells and target them for 
T cell-mediated elimination. HLA class I proteins (HLA-A, -C, and -B) present 
peptides from endogenous proteins to cytotoxic T lymphocytes. HLA class II proteins 
(HLA-DRB3/4/5, -DRB1, and -DQB1) present peptides derived from exogenous 
proteins to CD41 helper T cells. 
With regard to the possible role of HLA molecules in leukemia, a causative role of 
HLA in terms of presentation of a nonself-peptide (i.e. virus) or altered self-peptide 
(i.e. a mutated oncogene) is a possibility. However, this effect might be mediated by 
NK cells, known to control tumor transformation and viral infection.  In fact, HLA 
class I antigen, in particular HLA-C alleles, play a role as KIR ligands that play a 
crucial role in the activity of natural killer cells (Gragert et al 2014) 
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Fig. 12. The epidemiological study of allelic variants of the RHD, was approved by the 
President of SIMTI, Ph. Claudio Velati 
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8. DISCUSSION AND CONCLUSION  
 
This thesis highlights the importance of applying the scientific molecular method 
to transfusion medicine.  
It has been demonstrated that the history of transfusion medicine, was born with 
the need of man to cure incurable diseases and has legendary and controversial origins. 
The first approaches to  blood for therapeutic purposes were very different from we 
intend for "transfusion therapy": the blood was like a magic fluid capable of healing 
the wounds of soul before than body. So history shows that the first transfusion (made 
with oral administration) served to rejuvenate or to treat mental illness. In the Middle 
Ages bloodletting therapy was frequently used for release negative moods responsible 
of disease 
The beneficial and adverse effects generated a very painful story regard the use of 
blood for therapeutic purposes.  
The Renaissance, a time of important discoveries in medicine, is characterized by 
great contrasts. On the one hand, the growing scientific interest initiating the 
"experimental period"; the other the collection of data, among confirmations and 
denials, creates a general climate of distrust and doubts regarding the transfusion only 
heterologous and performed with primordial instruments (vein to vein) at that time. 
So, in Europe transfusions were not practiced throughout the XVIII century. 
The scientific discoveries of the XIX century and the need to treat the wounded in 
the First World War, gave great revival to the transfusion medicine and started the 
"Therapeutic period" that continues until the present day.  
Currently, transfusion medicine is open to many clinical fronts and has a great 
interest in the continuous innovations for transfusion therapy improvement. 
How might continued innovation contribute to improved transfusion therapy? 
According to M. Schilling ( professor of management and organizations at New York 
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University Stern School of Business) there are at least five approaches (table 5). 
(Schilling 2012) 
 
TYPES OF INNOVATION 
 
1. Improving products 
2. Improving process to produce a product 
3. Improve uses of existing products 
4. Identifying new uses of existing products 
5. Use existing processes to produce new 
products 
Table 5. Typing of technical innovation and strategic managements. (Schilling MA) 
 
1) Improving products. Recent examples of this approach in transfusion medicine 
are RBC additive solutions that extend storage; the introduction of leukoreduction for 
TRALI preventions; the introduction of pathogen inactivation of labile blood 
components (PLTs). Pathogen inactivation can be done with a psoralen-type 
compound that prevents DNA strands from replicating, or riboflavin and UV light that 
damages nucleic acids. Blood products treated with these methods are widely used and 
clinically effective. A fringe benefit of the pathogen inactivation techniques is that 
they prevent replication of lymphocytes and thus eliminate the need for irradiating 
blood products. (McCullough 2007; Schlenke 2014) 
2) Improving process to produce a product. In this case, aphaeresis plays a key 
role. The multicomponent production with aphaeresis introduced in the last decades, 
has allowed to improve the quality of the product (blood components) through the 
improvement of the production process. For example, there are simple devices now 
that are used to collect 2 units of RBCs from a single donor. Even more exciting is that 
these devices can be used to collect other combinations of components. Continued 
innovation by engineers can be expected to refine these devices to make it possible to 
collect any combination of components from each specific donor at the collection site. 
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This improves the standards of the product and reduces handling laboratory, producing 
blood components with more quality and safety Once that is possible the component 
laboratory may have outlived its usefulness.(Snyder et al 2003)  
3) Improved uses of existing products. A goal of modern transfusion medicine is to 
improve the appropriateness of prescribing blood components. This comes from 
awareness that a blood component, if is not necessary, can expose the recipient to the 
transfusion risks and the improper use reduces availability for other patients. So, have 
been carefully studied and declared the indications to transfusion therapy. Examples of 
this area are the evolution of the prophylactic PLT transfusion trigger to 10×10
9
/L or 
the lowered RBC transfusion trigger to 8 or 7g/dL, PLT crossmatching, and blood 
management programs (McCullough 2010). 
4) Identifying new uses of existing products. One of the challenges of transfusion 
research, is to know more precisely the properties of blood and its components. This 
has allowed to understand that platelets, for example, are not only protagonists of 
homeostasis, but platelet's granules contain growth factors able to stimulate tissue 
regeneration. So, the platelets can also be used for other purposes (regenerative 
medicine). Another eexamples is the use of IVIg in various autoimmune diseases and 
the use of plasma for replacement in exchange transfusions to treat thrombotic 
thrombocytopenic purpura (TTP): the use of plasma in the treatment of TTP has 
radically changed the natural history of the disease and improved the prognosis and 
life expectancy of patients. 
5) Use existing processes to produce new products. Novel cellular therapies or 
cord blood banking are examples of this type of innovation. The cord blood collection 
procedure is different from whole blood or apheresis collections, but the issues in cord 
blood banking are essentially the same for whole blood or apheresis. These issues 
include consent, medical evaluation of the donor, collection procedures, cell 
preservation, testing for safety and potency, and transfusion techniques. (Broxmeyer 
2013)  
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A large number of different novel cellular products are either being manufactured 
or under development. For instance, with the use of cell manipulation techniques it is 
possible to produce cytomegalovirus (CMV) cytotoxic T cells for treatment of CMV 
infection, CD4/25 regulatory T lymphocytes for prevention of GVHD, isolation of 
marrow cells for cardiac repair after myocardial infarction, T cells for the treatment of 
prostatic carcinoma, cytotoxic T lymphocytes to treat nasopharyngeal carcinoma due 
to EBV infection, T-depleted blood stem cell grafts to enhance engraftment, 
mesenchymal stem cells to treat sickle cell disease, autologous stem cells to repair 
small vessels in the legs to treat leg intermittent claudication, and cardiac stem cells 
for repair after myocardial infarction
2
.(Redd et al 2009) 
This thesis and the work performed during this PhD course highlight another 
aspect that contributes to transfusion therapy innovation: the improving of the 
molecular technologies application. 
This has important significance not only for the diagnosis of disease, but also in the 
identification of a targeted and personalized transfusion therapy.  
For example, molecular cloning and characterization of ADAMTS13 gene and protein 
structure have opened a new avenue for study of the biology and biochemistry of the 
ADAMTS13 protease. Development of a sensitive and speciﬁc assay for ADAMTS13 
activity and inhibitor would not only help to understand the pathogenesis of TTP, but 
also to facilitate a more timely and accurate clinical diagnosis, which is crucial for 
initiating and tailoring therapy in patients with TTP. 
The knowledge of the ADAMTS13 gene, have provided further insight into the 
structure-function relationships, biosynthesis, and regulation of the ADAMTS13 
protease. To date, more than 70 mutations on ADAMTS13 gene have been described 
in patients with congenital or familial TTP. The majority of these mutations are 
                                                          
2
 Examples of products being developed manufacture through the National Heart, Lung, and Blood 
Institute (NHLBI)-funded group called Production Assistance for Cellular Therapies (PACT)
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missense mutations involving cysteine residues and have been identiﬁed in patients 
with severe deficiency of plasma ADAMTS 13. So, the mutations on ADAMTS13 
gene has been considered to be the primary cause of congenital TTP.(Shelat et al 
2005)  
The presence of ADAMTS13 autoantibodies are rather speciﬁc for making a diagnosis 
of acquired TTP. In addition, a high titer of inhibitory autoantibodies correlates with 
more relapses (Tsai et al 1998). An ELISA assay along with Western blotting using 
the recombinant ADAMTS13 as an antigen has been developed recently, which can 
detect both inhibitory and non inhibitory autoantibodies. (Reiger et al 2005)  
Adjunct immune therapies such as rituximab, an anti-CD20 chimeric monoclonal 
antibody, or cyclophosphamide, may be considered to reduce inhibitory antibodies in 
patients with acute TTP who do not adequately respond to plasma exchange or are 
chronically relapsed (Fakhouri et al 2004). Therefore, a robust ADAMTS13 inhibitor 
assay is critical for understanding of the mechanism of TTP and for tailoring therapy. 
Another example is the study of the growth factors (GFs) used for tissue repair in 
regenerative medicine. Our study on the application of platelet gel in orthopedics, have 
demonstrated the potential to modify the natural healing pathway of tendons and 
ligaments in several ways. The action is related to the increased concentration of GFs 
and bioactive proteins released by activated platelets (Table 6), which seem able to 
help the regeneration of tissues that otherwise have low healing potential, potentially 
restoring biomechanical properties similar to normal tendons and ligaments (Taylor et 
al 2011). 
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Table 6. GFs Released by Activated Platelets (Taylor et al 2011) 
 
 
The application of PRP ampliﬁes the surge of chemical mediators to the 
microenvironment of the injured area, including platelet derived factors. The increased 
concentration of platelets and GFs mimics the initial stage of the inﬂammatory 
response, characterized by the migration of neutrophils, monocytes, and macrophages 
to the site of injury under the guidance of the chemical mediators. 
These cytokines mediate the initiation of neovascularization, tenocyte proliferation, 
ﬁbroblast proliferation, and further recruitment of inﬂammatory cells. In addition to 
the stimulatory effects of PRP on reparative cells, there is evidence that PRP may also 
have an inhibitory effect on certain pro-inﬂammatory cytokines that may be 
detrimental to the early stages of healing, speciﬁcally through suppression of IL-1 
release from activated macrophages. This dual action of enhancing repair and 
minimizing tissue breakdown may allow local PRP application to accelerate the tissue 
healing process, leading to a wide range of potential applications and potential 
advantages for improved outcomes and faster recovery.
11
 
Finally, an improvement in the application of molecular techniques, concerns the 
blood and HLA typing. Our data, underlined the importance of molecular biology in 
Immunohematology to discriminate aspects not easily identified by serology.  
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Today the blood banks of rare groups use of the latest generation molecular 
biology techniques (microarray and array) to type in extended erythrocyte antigens. 
Yet little explored is the genetic study of erythrocyte alloreactivity.  
Alloreativity is the production of alloantibodies (antibodies against erythrocyte 
antigens belonging to the minor blood groups) as a result of antigenic transfusion 
stimulus. The literature about alloreactivity, correlates to a precise set-HLA class II, 
which emphasizes the increased susceptibility of individuals to produce alloantibodies 
in the presence of the same antigenic stimulus (Gragert 2014). 
Therefore, our future prospects are oriented in a case-control study to evaluate 
serologically alloreactive subjects polytransfused (case) and not transfused (control) in 
order to correlate the HLA and immune response. 
Concluding, innovation in blood banking and transfusion medicine can be also  
considered based on the underlying science and technology or the organizations that 
fostered innovation. 
For continued innovation, transfusion medicine and blood banking must imbue a 
culture in which embrace the new and appreciate the value of innovation not just for a 
financial return on investment, but to improve medical care and provide value to 
patients.  
The transfusion community must be forward looking and open to new ways of 
doing things. A commitment from blood organizations to innovation will be essential: 
clinical trial sites and organizations willing to evaluate  and support these innovations, 
as a driving stimulus is dedication to continue to improve transfusion therapy for 
patients. 
During the past several decades, remarkable advances have led to improved 
transfusion therapy for patients. For continued innovation, it will be important to 
strengthen relationships with other scientific and technical disciplines and to attract 
talented young people into this field. 
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